<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:09:21Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10077489" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10077489</identifier>
        <datestamp>2023-04-07</datestamp>
        <setSpec>jciinsight</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JCI Insight</journal-id>
              <journal-id journal-id-type="iso-abbrev">JCI Insight</journal-id>
              <journal-id journal-id-type="publisher-id">JCI Insight</journal-id>
              <journal-title-group>
                <journal-title>JCI Insight</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2379-3708</issn>
              <publisher>
                <publisher-name>American Society for Clinical Investigation</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10077489</article-id>
              <article-id pub-id-type="pmcid">PMC10077489</article-id>
              <article-id pub-id-type="pmc-uid">10077489</article-id>
              <article-id pub-id-type="pmid">36749631</article-id>
              <article-id pub-id-type="pmid">36749631</article-id>
              <article-id pub-id-type="publisher-id">154164</article-id>
              <article-id pub-id-type="doi">10.1172/jci.insight.154164</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0001-6463-9020</contrib-id>
                  <name>
                    <surname>Crompton</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <email>m.crompton@bristol.ac.uk</email>
                  <xref rid="A1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ferguson</surname>
                    <given-names>Joanne K.</given-names>
                  </name>
                  <email>Joanne.Ferguson.2011@my.bristol.ac.uk</email>
                  <xref rid="A1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ramnath</surname>
                    <given-names>Raina D.</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Onions</surname>
                    <given-names>Karen L.</given-names>
                  </name>
                  <email>karen.onions@bristol.ac.uk</email>
                  <xref rid="A1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0002-3405-4563</contrib-id>
                  <name>
                    <surname>Ogier</surname>
                    <given-names>Anna S.</given-names>
                  </name>
                  <email>ao15041.2015@my.bristol.ac.uk</email>
                  <xref rid="A1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gamez</surname>
                    <given-names>Monica</given-names>
                  </name>
                  <email>mg14606@bristol.ac.u</email>
                  <xref rid="A1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Down</surname>
                    <given-names>Colin J.</given-names>
                  </name>
                  <email>colin.down@bristol.ac.uk</email>
                  <xref rid="A1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Skinner</surname>
                    <given-names>Laura</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wong</surname>
                    <given-names>Kitty H.</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dixon</surname>
                    <given-names>Lauren K.</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0002-6189-906X</contrib-id>
                  <name>
                    <surname>Sutak</surname>
                    <given-names>Judit</given-names>
                  </name>
                  <email>Judit.Sutak@nbt.nhs.uk</email>
                  <xref rid="A2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Harper</surname>
                    <given-names>Steven J.</given-names>
                  </name>
                  <email>S.Harper@bris.ac.uk</email>
                  <xref rid="A3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0002-7654-8318</contrib-id>
                  <name>
                    <surname>Pontrelli</surname>
                    <given-names>Paola</given-names>
                  </name>
                  <email>paola.pontrelli@uniba.it</email>
                  <xref rid="A4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gesualdo</surname>
                    <given-names>Loreto</given-names>
                  </name>
                  <email>loreto.gesualdo@uniba.it</email>
                  <xref rid="A4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Heerspink</surname>
                    <given-names>Hiddo L.</given-names>
                  </name>
                  <email>h.j.lambers.heerspink@med.umcg.nl</email>
                  <xref rid="A5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Toto</surname>
                    <given-names>Robert D.</given-names>
                  </name>
                  <email>robert.toto@utsouthwestern.edu</email>
                  <xref rid="A6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Welsh</surname>
                    <given-names>Gavin I.</given-names>
                  </name>
                  <email>G.I.Welsh@bristol.ac.uk</email>
                  <xref rid="A1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0002-9645-1476</contrib-id>
                  <name>
                    <surname>Foster</surname>
                    <given-names>Rebecca R.</given-names>
                  </name>
                  <email>becky.foster@bristol.ac.uk</email>
                  <xref rid="A1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Satchell</surname>
                    <given-names>Simon C.</given-names>
                  </name>
                  <email>s.c.satchell@bristol.ac.uk</email>
                  <xref rid="A1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0002-9814-8008</contrib-id>
                  <name>
                    <surname>Butler</surname>
                    <given-names>Matthew J.</given-names>
                  </name>
                  <email>Matthew.butler@bristol.ac.uk</email>
                  <xref rid="A1" ref-type="aff">1</xref>
                </contrib>
              </contrib-group>
              <aff id="A1"><label>1</label>Bristol Renal, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.</aff>
              <aff id="A2"><label>2</label>Pathology Department, Southmead Hospital, Bristol, United Kingdom.</aff>
              <aff id="A3"><label>3</label>School of Physiology, Pharmacology &amp; Neuroscience, University of Bristol, Bristol, United Kingdom.</aff>
              <aff id="A4"><label>4</label>Division of Nephrology, Dialysis and Transplantation, Department of Emergency and Organ Transplantation, Aldo Moro University of Bari, Bari, Italy.</aff>
              <aff id="A5"><label>5</label>Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, The Netherlands.</aff>
              <aff id="A6"><label>6</label>Department of Clinical Sciences, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.</aff>
              <author-notes>
                <corresp>Address correspondence to: Matthew J. Butler, Bristol Renal, Dorothy Hodgkin Building, Whitson St., Bristol, BS1 3NY, United Kingdom. Phone: 44.0.117.331.3086; Email: <email>matthew.butler@bristol.ac.uk</email>.</corresp>
                <fn>
                  <p><bold>Authorship note:</bold> MJB and SCS are co–senior authors.</p>
                </fn>
              </author-notes>
              <pub-date date-type="pub" publication-format="electronic" iso-8601-date="2023-03-08T12:00:00-0500">
                <day>8</day>
                <month>3</month>
                <year>2023</year>
              </pub-date>
              <pub-date date-type="collection" publication-format="electronic" iso-8601-date="2023-03-08T12:00:00-0500">
                <day>8</day>
                <month>3</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>8</day>
                <month>3</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>8</volume>
              <issue>5</issue>
              <elocation-id>e154164</elocation-id>
              <history>
                <date date-type="received">
                  <day>16</day>
                  <month>8</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>23</day>
                  <month>1</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2023 Crompton et al.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <copyright-holder>Crompton et al.</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <ext-link xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="https://insight.jci.org/articles/view/154164">This article is available online at https://insight.jci.org/articles/view/154164</self-uri>
              <abstract>
                <p>The glomerular endothelial glycocalyx (GEnGlx) forms the first part of the glomerular filtration barrier. Previously, we showed that mineralocorticoid receptor (MR) activation caused GEnGlx damage and albuminuria. In this study, we investigated whether MR antagonism could limit albuminuria in diabetes and studied the site of action. Streptozotocin-induced diabetic Wistar rats developed albuminuria, increased glomerular albumin permeability (P<italic toggle="yes">s’<sub>alb</sub></italic>), and increased glomerular matrix metalloproteinase (MMP) activity with corresponding GEnGlx loss. MR antagonism prevented albuminuria progression, restored P<italic toggle="yes">s’<sub>alb</sub></italic>, preserved GEnGlx, and reduced MMP activity. Enzymatic degradation of the GEnGlx negated the benefits of MR antagonism, confirming their dependence on GEnGlx integrity. Exposing human glomerular endothelial cells (GEnC) to diabetic conditions in vitro increased MMPs and caused glycocalyx damage. Amelioration of these effects confirmed a direct effect of MR antagonism on GEnC. To confirm relevance to human disease, we used a potentially novel confocal imaging method to show loss of GEnGlx in renal biopsy specimens from patients with diabetic nephropathy (DN). In addition, patients with DN randomized to receive an MR antagonist had reduced urinary MMP2 activity and albuminuria compared with placebo and baseline levels. Taken together, our work suggests that MR antagonists reduce MMP activity and thereby preserve GEnGlx, resulting in reduced glomerular permeability and albuminuria in diabetes.</p>
              </abstract>
              <abstract abstract-type="graphical">
                <p>
                  <graphic xlink:href="jciinsight-8-154164-g200.jpg" position="float"/>
                </p>
              </abstract>
              <kwd-group kwd-group-type="specialties">
                <kwd>Endocrinology</kwd>
                <kwd>Nephrology</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="keywords">
                <kwd>Chronic kidney disease</kwd>
                <kwd>Diabetes</kwd>
                <kwd>Glycobiology</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution>Kidney Research UK</institution>
                      <institution-id>https://doi.org/10.13039/501100000291</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>RP_031_20180306,JF-S/RP/2015/10,RP_002_20190917,ID_004_20170330,IN_004_20190305</award-id>
                </award-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution>Diabetes UK</institution>
                      <institution-id>https://doi.org/10.13039/501100000361</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>18/0005795</award-id>
                </award-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution>British Heart Foundation</institution>
                      <institution-id>https://doi.org/10.13039/501100000274</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>PG/15/81/31740</award-id>
                </award-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution>Medical Research Council</institution>
                      <institution-id>https://doi.org/10.13039/501100000265</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>MR/M018237/1</award-id>
                </award-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution>Horizon 2020</institution>
                      <institution-id>https://doi.org/10.13039/501100007601</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>115974</award-id>
                </award-group>
                <award-group>
                  <funding-source>See list below</funding-source>
                  <award-id>See list below</award-id>
                </award-group>
                <funding-statement>P.P., L.G., H.L.H. and S.C.S. are members of the Biomarker Enterprise to Attack Diabetic Kidney Disease (BEAt-DKD) consortium and as such this project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115974. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and JDRF. Any dissemination of results reflects only the author’s view; the JU is not responsible for any use that may be made of the information it contains.</funding-statement>
                <funding-statement>See list below</funding-statement>
              </funding-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro">
              <title>Introduction</title>
              <p>Glomerular diseases, including diabetic nephropathy (DN), are the most common cause of end-stage renal failure (<xref rid="B1" ref-type="bibr">1</xref>). Approximately 1 in 5 people with diabetes need treatment for DN during their lifetime (<xref rid="B2" ref-type="bibr">2</xref>). In 2018, more than 700,000 people in the United States were being treated for end-stage renal disease (ESRD), and diabetes accounted for 47% of all new ESRD cases (<xref rid="B3" ref-type="bibr">3</xref>). Renin-angiotensin-aldosterone system (RAAS) blockade with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARB) reduce albuminuria and the risk of ESRD (<xref rid="B4" ref-type="bibr">4</xref>). However, because of aldosterone escape, use of an ACEi or ARB may not reduce aldosterone-mediated mineralocorticoid receptor (MR) stimulation (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). In DN, the addition of an MR antagonist to ACEi or ARB therapy further reduces albuminuria, suggesting MR activation directly contributes to albuminuria (<xref rid="B7" ref-type="bibr">7</xref>–<xref rid="B12" ref-type="bibr">12</xref>). Most recently, the large Phase III FIDELIO-DKD trial reported that, in patients with chronic kidney disease (CKD) and type 2 diabetes, MR antagonism reduced the risk of CKD progression, albuminuria, and cardiovascular events (<xref rid="B13" ref-type="bibr">13</xref>). However, side effects, including hyperkalemia, limit the clinical use of MR antagonists (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B14" ref-type="bibr">14</xref>–<xref rid="B16" ref-type="bibr">16</xref>). Thus, a better definition of the mechanisms of glomerular protection mediated by MR antagonists is needed to identify novel tissue-specific therapeutic targets.</p>
              <p>MR is expressed in the vascular endothelium (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>) and is also expressed in glomerular endothelial cells (GEnC) (<xref rid="B19" ref-type="bibr">19</xref>) — highly specialized fenestrated vascular endothelial cells. Changes in the glomerular endothelium are increasingly recognized in DN and other glomerular diseases (<xref rid="B20" ref-type="bibr">20</xref>). The glomerulus is the filtering unit of the kidney. Its function is dependent on the multilayer structure of the glomerular filtration barrier (GFB) consisting of GEnC, glomerular basement membrane (GBM), and podocytes (<xref rid="B21" ref-type="bibr">21</xref>). The glomerular endothelial glycocalyx (GEnGlx) covers the luminal surface of the GEnC, filling the fenestrations and contributing to GFB function (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). Our group and others have shown that GEnGlx specifically limits albumin permeability in vitro (<xref rid="B24" ref-type="bibr">24</xref>–<xref rid="B26" ref-type="bibr">26</xref>) and in vivo (<xref rid="B27" ref-type="bibr">27</xref>–<xref rid="B30" ref-type="bibr">30</xref>). The EnGlx is a hydrated poly-anionic gel composed principally of proteoglycan core proteins, glycosaminoglycan chains, and sialoglycoproteins (<xref rid="B31" ref-type="bibr">31</xref>). In healthy vascular physiology, the EnGlx has multiple roles, including regulating vascular permeability (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>), mediating shear stress mechanotransduction (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>), and attenuating immune cell–endothelium interactions (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>), with further roles under investigation (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>). Disruption of the EnGlx occurs in multiple clinical conditions, including diabetes, sepsis, preeclampsia, and atherosclerosis (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B40" ref-type="bibr">40</xref>).</p>
              <p>In humans, DN is characterized by albuminuria (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B41" ref-type="bibr">41</xref>). In early DN, no macroscopic GBM or podocyte changes are detectable, but systemic endothelial and Glx dysfunction in both type 1 (<xref rid="B42" ref-type="bibr">42</xref>) and type 2 (<xref rid="B43" ref-type="bibr">43</xref>) diabetes have been shown to occur. Others have previously shown that glycosaminoglycans are lost from the GFB in diabetes (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>), and we have confirmed GEnGlx loss in diabetic mice (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>) and rats (<xref rid="B30" ref-type="bibr">30</xref>). Together, these findings strongly implicate GEnGlx damage as a key initiator of albuminuria in DN (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B41" ref-type="bibr">41</xref>).</p>
              <p>EnGlx components are cleaved from the cell surface by sheddases, including matrix metalloproteinases (MMPs) (<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>). We have recently defined a pathway whereby excess MR activation results in increased MMP2 and MMP9 activity and consequent GEnGlx dysfunction and albuminuria (<xref rid="B19" ref-type="bibr">19</xref>). Here, we sought to determine whether this pathological pathway contributes to GEnGlx damage in diabetes, hypothesizing that MR antagonism reduces MMP activity in diabetes, preserving the GEnGlx and limiting the development of albuminuria. Hence, we sought to determine whether MR antagonism, with spironolactone, could prevent the development of albuminuria in a DN rat model by preserving the GEnGlx to maintain the GFB. Furthermore, we examined GEnGlx damage and MR-mediated MMP inhibition in human DN.</p>
            </sec>
            <sec sec-type="results">
              <title>Results</title>
              <sec>
                <title>Development of albuminuria and increased glomerular permeability in early DN is ameliorated by MR antagonism.</title>
                <p>After receiving streptozotocin (STZ), rats were hyperglycemic at week 3 (<xref rid="sd" ref-type="sec">Supplemental Figure 1A</xref>; supplemental material available online with this article; <ext-link xlink:href="https://doi.org/10.1172/jci.insight.154164DS1" ext-link-type="uri">https://doi.org/10.1172/jci.insight.154164DS1</ext-link>). STZ-induced diabetic rats gained significantly less weight than controls. Spironolactone treatment had no significant impact on body weight (<xref rid="sd" ref-type="sec">Supplemental Figure 1B</xref>). Diabetic rats developed albuminuria by week 4 (<xref rid="sd" ref-type="sec">Supplemental Figure 1C</xref>). Spironolactone significantly reduced albuminuria in diabetic rats compared with vehicle. The fold change in urinary albumin/creatinine ratio (uACR) in vehicle-treated diabetic rats significantly increased compared with controls and spironolactone-treated diabetic rats (<xref rid="F1" ref-type="fig">Figure 1B</xref>). There was no significant difference in uACR fold change between spironolactone-treated diabetic rats and controls. Similarly, diabetic rats had a significant increase in fold change of total protein/creatinine ratio (<xref rid="sd" ref-type="sec">Supplemental Figure 1D</xref>). Our glomerular permeability assay was used to directly measure the albumin permeability (P<italic toggle="yes">s’<sub>alb</sub></italic>) of individually trapped glomeruli (<xref rid="B30" ref-type="bibr">30</xref>). In contrast to urine-based measurements, this ex vivo assay directly measures the GFB permeability to albumin in isolation, independently of hemodynamic factors and tubular albumin handling (<xref rid="F1" ref-type="fig">Figure 1C</xref>). Increased glomerular capillary wall protein permeability was confirmed by an increase in P<italic toggle="yes">s’<sub>alb</sub></italic> (<xref rid="F1" ref-type="fig">Figure 1D</xref>). Spironolactone restored P<italic toggle="yes">s’<sub>alb</sub></italic> to control values, significantly reducing P<italic toggle="yes">s’<sub>alb</sub></italic> compared with vehicle-treated diabetic rats.</p>
              </sec>
              <sec>
                <title>Diabetes-induced GEnGlx damage in early DN is prevented by MR antagonism.</title>
                <p><italic toggle="yes">Marasmium oreades</italic> agglutinin (MOA) and wheat germ agglutinin (WGA) lectins both bound to the EnGlx on the luminal surface of the labeled GEnC membrane (<xref rid="F2" ref-type="fig">Figure 2A</xref>). We analyzed the images generated using a fluorescence profile peak-to-peak measurement technique (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B50" ref-type="bibr">50</xref>) to provide an index of GEnGlx thickness (<xref rid="F2" ref-type="fig">Figure 2B</xref>). Manual peak-to-peak measurement of MOA labeling demonstrated a reduction in GEnGlx thickness in diabetic rats (<xref rid="F2" ref-type="fig">Figure 2C</xref>). Spironolactone treatment in diabetic rats restored the GEnGlx thickness, with no significant differences compared with controls. P<italic toggle="yes">s’<sub>alb</sub></italic> correlated inversely with the GEnGlx thickness measured by peak-to-peak analysis of MOA/R18 labeling (<xref rid="F2" ref-type="fig">Figure 2D</xref>). To confirm the validity of our findings with MOA labeling, we applied a second lectin, WGA, for peak-to-peak measurements, and we developed an automated methodology. As with MOA, we found significant Glx damage in diabetic rats, with a decrease in GEnGlx thickness (<xref rid="F2" ref-type="fig">Figure 2E</xref>). Spironolactone treatment significantly restored the GEnGlx thickness, with no significant differences compared with controls. Again, P<italic toggle="yes">s’<sub>alb</sub></italic> changes correlated inversely, and strongly, with GEnGlx thickness measured from peak to peak of WGA/octadecyl rhodamine B chloride (WGA/R18) labeling (<xref rid="F2" ref-type="fig">Figure 2F</xref>). Perfusion-fixed, Alcian blue–labeled, kidneys were used for transmission electron microscopy (TEM) of the glomerular capillary wall to validate peak-to-peak assessment of the Glx (<xref rid="sd" ref-type="sec">Supplemental Figure 2A</xref>) and study GFB changes (<xref rid="sd" ref-type="sec">Supplemental Figure 3A</xref>) (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B46" ref-type="bibr">46</xref>). Diabetic rats had decreased GEnGlx coverage and thickness, which were both restored by spironolactone treatment (<xref rid="sd" ref-type="sec">Supplemental Figure 2</xref>, B and C). P<italic toggle="yes">s’<sub>alb</sub></italic> changes were weakly associated with GEnGlx thickness measured by electron microscopy (EM) (<xref rid="sd" ref-type="sec">Supplemental Figure 2D</xref>), suggesting that peak-to-peak assessment provides a superior measure of Glx structural and functional integrity. Mesangial matrix expansion was assessed using periodic acid–Schiff staining, with no significant changes in glomerular fibrosis in diabetic rats (<xref rid="sd" ref-type="sec">Supplemental Figure 1</xref>, E and F). In addition, comprehensive TEM analysis confirmed that no other significant ultrastructural changes were visible (<xref rid="sd" ref-type="sec">Supplemental Figure 3</xref>, B–H), further confirming that this model represents early DN.</p>
              </sec>
              <sec>
                <title>The effect of MR antagonism in preventing the diabetes-induced increase in glomerular permeability is dependent on the GEnGlx.</title>
                <p>Hyaluronidase, a Glx-degrading enzyme, was infused in a subgroup of spironolactone-treated diabetic rats to remove the EnGlx to confirm the importance of GEnGlx preservation in this model (<xref rid="F3" ref-type="fig">Figure 3A</xref>). Automated peak-to-peak measurement of both MOA and WGA labeling confirmed significant reductions in GEnGlx thickness following enzyme infusion (<xref rid="F3" ref-type="fig">Figure 3, B and C</xref>). Enzymatic degradation of the GEnGlx significantly increased the uACR and returned albuminuria to diabetes-induced levels (<xref rid="F3" ref-type="fig">Figure 3D</xref>). TEM image analysis confirmed that hyaluronidase caused significant GEnGlx loss (<xref rid="sd" ref-type="sec">Supplemental Figure 4</xref>, A–C). No significant effect on either podocyte Glx (pGlx) or other filtration barrier components were detectable (<xref rid="sd" ref-type="sec">Supplemental Figure 4</xref>, D–J), confirming that hyaluronidase activity remained focused on the luminal EnGlx.</p>
              </sec>
              <sec>
                <title>Increased MMP activity in early DN is ameliorated by MR antagonism.</title>
                <p>We have previously identified MMP2 and MMP9 as key Glx sheddases (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B49" ref-type="bibr">49</xref>). Plasma, glomerular, and urine active MMP2 were significantly increased in diabetic rats, compared with controls (<xref rid="F4" ref-type="fig">Figure 4, A–C</xref>). Similarly, plasma, glomerular, and urine active MMP9 were significantly increased in diabetic rats compared with controls (<xref rid="F4" ref-type="fig">Figure 4, D–F</xref>). Therapeutic treatment with spironolactone significantly reduced glomerular active MMP9, with no significant differences compared with controls (<xref rid="F4" ref-type="fig">Figure 4E</xref>). In addition, spironolactone significantly attenuated the diabetes-induced increase in both urine MMP2 and MMP9 activities (<xref rid="F4" ref-type="fig">Figure 4, C and F</xref>), confirming that MR antagonism reduced the activity of both MMPs in vivo.</p>
              </sec>
              <sec>
                <title>Exposing human GEnC to diabetic conditions resulted in MMP upregulation and GEnGlx damage that were both ameliorated by MR antagonism.</title>
                <p>Secreted gelatinases MMP2 and MMP9 can be activated by cell membrane–bound membrane type 1 MMP, also known as MMP14 (<xref rid="B51" ref-type="bibr">51</xref>–<xref rid="B53" ref-type="bibr">53</xref>). We therefore investigated if localized endothelial production and activation could contribute to GEnCGlx degradation in diabetes. To mimic the diabetic milieu in vitro, conditionally immortalized (Ci) human GEnC were exposed to increased concentrations of glucose, insulin, TNF-α, and IL-6 (<xref rid="B54" ref-type="bibr">54</xref>). MMP2, MMP9, and MMP14 expression significantly increased under diabetic conditions (<xref rid="F5" ref-type="fig">Figure 5, A–F</xref>). Spironolactone prevented these increases. WGA lectin glycocalyx staining (<xref rid="sd" ref-type="sec">Supplemental Figure 5</xref>, A and B) was reduced following exposure to diabetic conditions, and spironolactone limited the reduction in WGA lectin glycocalyx staining, suggesting glycocalyx preservation (<xref rid="F5" ref-type="fig">Figure 5, G and H</xref>). In addition, <italic toggle="yes">MMP2</italic>, <italic toggle="yes">MMP9</italic>, and <italic toggle="yes">MMP14</italic> gene expression was significantly increased in GEnC exposed to diabetic conditions (<xref rid="sd" ref-type="sec">Supplemental Figure 5</xref>, C–E). Spironolactone reduced this diabetes-induced increase in <italic toggle="yes">MMP</italic> mRNA, although this was only significant with <italic toggle="yes">MMP14</italic>. These effects happen in isolation from other cell types, demonstrating a direct targeted effect of spironolactone on GEnC.</p>
              </sec>
              <sec>
                <title>The GEnGlx is damaged in human DN.</title>
                <p>Human renal biopsies were obtained from two centers (Bristol, United Kingdom; Bari, Italy) (<xref rid="T1" ref-type="table">Table 1</xref>). <italic toggle="yes">Ulex europaeus</italic> agglutinin I (UEA-I) lectin has been established as an excellent marker for human endothelial cells (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>) and binds specifically to the EnGlx on the luminal surface of the GEnC (<xref rid="F6" ref-type="fig">Figure 6A</xref>). Representative images highlight the reduction in UEA-I labeling in renal biopsies from patients with DN when compared with thin basement membrane nephropathy (TBMN) controls or histologically normal controls. Following extensive validation in rodents, our peak-to-peak measurement technique has allowed us to confirm that GEnGlx damage occurs in human DN and is likely to contribute to the disease phenotype. Peak-to-peak measurement of UEA-I labeling, with our blinded automated methodology, demonstrated a significant reduction in GEnGlx thickness in patients with DN (<xref rid="F6" ref-type="fig">Figure 6, B and C</xref>). This was observed in renal biopsies from both the Bristol and Bari cohorts, when compared with TBMN controls or histologically normal controls respectively.</p>
              </sec>
              <sec>
                <title>MR antagonism in human diabetes reduces urinary MMP activity.</title>
                <p>Previously, Mehdi et al. confirmed that the addition of spironolactone to a regimen including maximal ACE inhibition improved renoprotection in DN (<xref rid="B57" ref-type="bibr">57</xref>). In this study, the significant reduction in albuminuria (compared with placebo and baseline) occurred despite no significant effect on ambulatory or clinic blood pressure (BP). Urine samples obtained from this clinical trial (<xref rid="T2" ref-type="table">Table 2</xref>) confirmed that, after 48 weeks of treatment, both urine active MMP2 and MMP9 in spironolactone-treated patients were significantly reduced (relative to placebo-treated patients) (<xref rid="F7" ref-type="fig">Figure 7, A and B</xref>). Urine active MMP2 level decreased significantly from baseline in the spironolactone group but not in the placebo group (<xref rid="F7" ref-type="fig">Figure 7A</xref>). The response to intervention for each individual subject demonstrated that 12 of 15 participants randomized to spironolactone experienced a decrease in the urinary MMP2 activity (<xref rid="F7" ref-type="fig">Figure 7A</xref>). The effects on MMP9 were more modest, as previously reported, in human disease (<xref rid="B58" ref-type="bibr">58</xref>).</p>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>Discussion</title>
              <p>Using a rat model of diabetes, we have demonstrated that upregulation of MMPs, GEnGlx damage, and glomerular dysfunction develop rapidly before other visible markers of DN. MR antagonism preserved the GEnGlx and restored GFB function. In vitro, using human GEnC exposed to a diabetic environment, we also observed upregulation of MMPs and glycocalyx damage, effects ameliorated by MR antagonism. In addition, we confirmed that GEnGlx damage occurs in human DN and may contribute to the disease phenotype. Finally, we have demonstrated that MR antagonism in human DN reduced MMP activity, with associated reductions in albuminuria. Together, these data suggest that alternative approaches to limit MMP activity and GEnGlx damage may reproduce the effect of MR inhibition while limiting side effects.</p>
              <p>STZ-induced diabetic rats provide a good model of early changes in DN (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B60" ref-type="bibr">60</xref>). Experiments using pancreatic islet transplantation confirm that albuminuria is due to DN, not STZ toxicity (<xref rid="B61" ref-type="bibr">61</xref>). Our diabetic rats progressively developed albuminuria; however, we found that urinary albumin excretion is not a sensitive measure of glomerular permeability, likely due to variable tubular albumin reabsorption and local hemodynamic alterations. Our glomerular P<italic toggle="yes">s’<sub>alb</sub></italic> assay directly measures the albumin permeability of capillary loops within isolated glomeruli, removing the effect of tubular albumin reuptake and hemodynamic factors (including changes in systemic BP) (<xref rid="B30" ref-type="bibr">30</xref>). We observed an increase in glomerular P<italic toggle="yes">s’<sub>alb</sub></italic> in early DN, and both P<italic toggle="yes">s’<sub>alb</sub></italic> and albuminuria were limited by MR antagonism, confirming a direct action on the GFB.</p>
              <p>The GEnGlx plays an important role in GFB function, limiting albumin permeability (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B28" ref-type="bibr">28</xref>). TEM is often used to directly visualize and measure the EnGlx (<xref rid="B62" ref-type="bibr">62</xref>–<xref rid="B64" ref-type="bibr">64</xref>); however, damage to the EnGlx during tissue preparation can introduce variability (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>). Sample fixation also affects quantification of EnGlx, with perfusion-fixation rather than immersion-fixation of tissue preferred (<xref rid="B65" ref-type="bibr">65</xref>). However, variable tissue perfusion in disease potentially confounds this technique, with a subjective increase in renal perfusion variability noted in diabetic animals. Furthermore, perfusion-fixation techniques are not applicable in humans. TEM analysis showed reduced GEnGlx coverage in diabetic rats, restored by inhibiting MR. However, TEM-derived GEnGlx measures showed only a weak correlation with P<italic toggle="yes">s’<sub>alb</sub></italic>. In mice, MOA lectin is known to bind to specific carbohydrate sequences present in the GEnGlx (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>), and here, we confirmed that it bound to the Glx on the luminal surface of the R18-labeled GEnC in rats. WGA lectin is also known to bind to the EnGlx in rats (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B68" ref-type="bibr">68</xref>), and with MOA, lectin was used to study the GEnGlx. Our peak-to-peak technique has previously been used, in vivo (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B50" ref-type="bibr">50</xref>) and on fixed kidney tissue (<xref rid="B47" ref-type="bibr">47</xref>), to provide an index of Glx thickness. Using both MOA and WGA lectin labeling, we have demonstrated that diabetes-induced reductions in GEnGlx thickness are restored by MR antagonism. In addition, GEnGlx thickness measured by peak-to-peak image analysis correlated with P<italic toggle="yes">s’<sub>alb</sub></italic> more strongly than TEM-based measurements. We find that peak-to-peak measurements (using optimized lectin/R18 labeling) are consistently thicker than measures using TEM and are closer to estimates made using atomic force microscopy (<xref rid="B69" ref-type="bibr">69</xref>–<xref rid="B72" ref-type="bibr">72</xref>) and solute exclusion (<xref rid="B73" ref-type="bibr">73</xref>–<xref rid="B75" ref-type="bibr">75</xref>). This is likely due to variable perfusion-fixation and EnGlx collapse during the dehydration process required for TEM imaging (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B76" ref-type="bibr">76</xref>). These findings further validate our peak-to-peak image analysis technique as a cheap, reliable, and robust alternative measure of EnGlx changes. Other glomerular ultrastructural features were not affected in this early disease model; for instance, STZ-induced diabetic rats did not develop GBM thickening or podocyte effacement by 8 weeks. In addition, no glomerular fibrosis was observed. These data confirm our previous observations that isolated disruption of GEnGlx in early DN is associated with albuminuria and increased P<italic toggle="yes">s’<sub>alb</sub></italic> (<xref rid="B30" ref-type="bibr">30</xref>).</p>
              <p>Hyaluronan is a key Glx component that is shed in diabetes (<xref rid="B77" ref-type="bibr">77</xref>). Using hyaluronidase to enzymatically degrade the GEnGlx in spironolactone-treated diabetic rats, we demonstrated that stripping the restored Glx increased albuminuria back to diabetes-induced levels, confirming the importance of GEnGlx preservation in this model. Previously in mice, using a combination of hyaluronidase and chondroitinase, we have shown that enzymatic GEnGlx depletion resulted in a significant increase in endothelial permeability (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B78" ref-type="bibr">78</xref>). Here, we used hyaluronidase in isolation hypothesizing that the short half-life in circulation (3.2 minutes in rats) (<xref rid="B79" ref-type="bibr">79</xref>) and molecular weight (61 kDa) would limit its effects to the EnGlx. TEM confirmed that hyaluronidase reduced the GEnGlx, without affecting pGlx or other glomerular components, confirming that focused, isolated glycocalyx injury occurs following acute hyaluronidase infusion, as seen following chronic hyaluronidase infusion (<xref rid="B80" ref-type="bibr">80</xref>).</p>
              <p>MR-induced MMPs are likely to contribute to Glx damage in DN. In mice, we have demonstrated increased MMP activity induced by excess aldosterone (<xref rid="B19" ref-type="bibr">19</xref>) and diabetes (<xref rid="B47" ref-type="bibr">47</xref>) and have shown that inhibiting MMPs directly afforded significant GEnGlx protection (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B47" ref-type="bibr">47</xref>). Here we have shown increased plasma, glomerular, and urine active MMP2 and MMP9 in diabetic rats and have shown successful inhibition of this effect using the MR antagonist spironolactone, a drug already approved for clinical use. These findings are consistent with our previously published work using vascular endothelial growth factor A<sub>165</sub>b, angiopoietin-1, and an MMP2/9 inhibitor where, in each case, GEnGlx restoration successfully reduced glomerular permeability in early DN (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>).</p>
              <p>MR is widely expressed by vascular endothelial cells, including GEnC, (<xref rid="B17" ref-type="bibr">17</xref>–<xref rid="B19" ref-type="bibr">19</xref>), but it is also expressed in a variety of other cell types within the kidney (<xref rid="B81" ref-type="bibr">81</xref>–<xref rid="B86" ref-type="bibr">86</xref>) and blood (<xref rid="B87" ref-type="bibr">87</xref>–<xref rid="B90" ref-type="bibr">90</xref>). These various targets may contribute to the beneficial effects of the MR antagonism in DN. However, we have shown previously that GEnC upregulate <italic toggle="yes">MMP2</italic> and <italic toggle="yes">MMP9</italic> mRNA in response to diabetic conditions or aldosterone excess in vitro, with associated increases in MMP activity suggesting that a direct effect is likely (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B47" ref-type="bibr">47</xref>). In this study, we observed an increase in glomerular P<italic toggle="yes">s’<sub>alb</sub></italic> following diabetes onset that was reduced by MR antagonism measured using an ex vivo assay (<xref rid="B30" ref-type="bibr">30</xref>) independent of hemodynamic factors and tubular albumin reuptake. This confirmed a direct action of MR antagonism on the GFB. When studied by EM and light microscopy, the only detectable changes in this model were focused within the GEnGlx. Furthermore, utilizing human CiGEnC, we have shown increased MMP2, MMP9, and MMP14 protein expression in GEnC exposed to chronic diabetic conditions, with an associated reduction in Glx. MR antagonism with spironolactone successfully inhibited these effects, suggesting a direct targeted effect of spironolactone on GEnC. To further investigate the key sites of MR antagonism, future work is planned utilizing cell type–specific deletion of MR in DN models.</p>
              <p>In humans, the absence of GBM and podocyte changes in early disease, along with systemic endothelial and Glx dysfunction seen in both type 1 (<xref rid="B42" ref-type="bibr">42</xref>) and type 2 (<xref rid="B43" ref-type="bibr">43</xref>) diabetes, strongly implicate GEnGlx damage as a key early event in DN development (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B41" ref-type="bibr">41</xref>). Here we have confirmed that GEnGlx damage occurs in human DN and may contribute to the disease phenotype. Great care has been taken to ensure that all samples were collected and processed identically. This ensured the Glx alterations seen between healthy, TBMN, and DN biopsies were the result of the primary pathology, not the collection technique. Confirming Glx damage in human DN highlights the importance of identifying therapeutic targets capable of limiting EnGlx degradation in disease. Such therapies could be of great benefit in both glomerular and systemic vascular disease (<xref rid="B91" ref-type="bibr">91</xref>–<xref rid="B93" ref-type="bibr">93</xref>). Previously, the addition of spironolactone to a regimen including maximal ACE inhibition has been shown to afford greater renoprotection in human DN (<xref rid="B57" ref-type="bibr">57</xref>). Compared with placebo, the uACR significantly decreased following spironolactone. Importantly in this study, BP treatment response was no different between placebo and spironolactone groups, suggesting a mechanism of action beyond BP control (<xref rid="B57" ref-type="bibr">57</xref>). However, the serum potassium level was significantly higher following the addition of spironolactone (<xref rid="B57" ref-type="bibr">57</xref>), and hyperkalemia continues to limit the clinical use of MR antagonists (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B12" ref-type="bibr">12</xref>–<xref rid="B16" ref-type="bibr">16</xref>). Most recently, the FIDELIO-DKD trial reported that MR antagonism, with finerenone, lowered the risk of CKD progression, reduced albuminuria, and reduced cardiovascular events in patients with CKD and type 2 diabetes, further highlighting the utility of MR antagonists in clinical practice (<xref rid="B13" ref-type="bibr">13</xref>). Previously, studies in patients with type 1 and type 2 diabetes have found increased plasma MMP2 levels (<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B94" ref-type="bibr">94</xref>, <xref rid="B95" ref-type="bibr">95</xref>) and elevated activities of urinary MMP2 and MMP9 (<xref rid="B96" ref-type="bibr">96</xref>–<xref rid="B98" ref-type="bibr">98</xref>). Spironolactone treatment has been shown to reduce MMP2 and MMP9 levels in patients at risk of heart failure (<xref rid="B99" ref-type="bibr">99</xref>–<xref rid="B101" ref-type="bibr">101</xref>). Using urine obtained from the Mehdi et al. clinical trial (<xref rid="B57" ref-type="bibr">57</xref>), we have shown that the addition of MR antagonism to maximal ACE inhibition in patients with DN reduced urine active MMP2 and MMP9 compared with placebo, with an associated reduction in albuminuria. This highlights that common mechanisms of Glx damage are likely in both human DN and rodent models of disease.</p>
              <p>In summary, we have shown that MR antagonism prevented damage to the GEnGlx and normalized glomerular albumin permeability in early DN. By applying potentially novel, validated techniques, we have demonstrated that GEnGlx damage may contribute to the disease phenotype in human DN. In addition, MR antagonism in DN reduced MMP activity, highlighting a mechanism of Glx protection. Alternative approaches to block MR-induced GEnGlx dysfunction, to reproduce the benefit of MR antagonists in DN without the adverse effects, warrant further investigation.</p>
            </sec>
            <sec sec-type="methods">
              <title>Methods</title>
              <sec>
                <title>Animals.</title>
                <p>Male Wistar rats (150–200 g, Charles River Laboratories) were maintained by the Animal Services Unit, University of Bristol. Animals were housed in a conventional facility with a controlled environment (21°C–24°C and 12:12 hour light/dark cycle). Timelines of the experimental protocols used are included (<xref rid="F1" ref-type="fig">Figure 1A</xref> and <xref rid="F3" ref-type="fig">Figure 3A</xref>).</p>
              </sec>
              <sec>
                <title>Type 1 diabetic model.</title>
                <p>For induction of diabetes, randomized rats were injected i.p. with 50 mg/kg STZ (S0130; Sigma-Aldrich) by adding the appropriate volume of the drug at 25 mg/mL in 10 mM sodium citrate (pH 4.5). Comparisons were made with vehicle-treated rats (10 mM sodium citrate [pH 4.5]). Glycemia, by tail-tip blood droplet analysis using a glucometer (Accu-Chek Aviva; Roche), was measured 3 weeks after STZ, and rats with glycemia ≥ 15 mmol/L were considered diabetic and included in the study.</p>
                <p>To confirm whether MR antagonism could preserve the GEnGlx and limit the development of DN, from 4 weeks after STZ administration, randomized diabetic rats were given daily s.c. injections of spironolactone (S3378; Sigma-Aldrich) at 50 mg/kg made up in corn oil (C8267; Sigma-Aldrich) for 28 days, and comparisons were made with vehicle-treated diabetic rats (corn oil). This spironolactone dose has previously been shown to have no effect on BP (<xref rid="B102" ref-type="bibr">102</xref>–<xref rid="B105" ref-type="bibr">105</xref>).</p>
                <p>To determine the importance of GEnGlx preservation in this model, enzymatic degradation of the GEnGlx with hyaluronidase was used. Briefly, randomized diabetic rats treated with spironolactone were given hyaluronidase (H3506; Sigma-Aldrich), 200 units in 1 mL, via tail vein injection 1 hour before being culled for tissue collection.</p>
                <p>Body weight was monitored regularly after STZ, and rats were placed on hydrophobic sand to collect urine. Urinary albumin was quantified with a rat albumin ELISA (E111-125, Bethyl Laboratories), and creatinine was measured using an enzymatic spectrophotometric assay (Konelab T-Series 981845; Thermo Fisher Scientific). uACR and urinary protein/creatinine ratio (uPCR) were calculated as previously described (<xref rid="B46" ref-type="bibr">46</xref>). Rats were culled at 8 weeks after STZ injection for tissue collection.</p>
              </sec>
              <sec>
                <title>Tissue collection.</title>
                <p>For tissue collection, rats were anesthetized with isoflurane in 1 L/min oxygen. A midline laparotomy was performed, and the abdominal aorta was cannulated with PE-10 tubing (427400; Becton Dickinson) to flush both kidneys with Ringer solution (NaCl, 132 mM; KCl, 4.6 mM; MgSO<sub>4</sub>-7H<sub>2</sub>O, 1.27 mM; CaCl<sub>2</sub>-2H<sub>2</sub>O, 2 mM; NaHCO<sub>3</sub>, 25 mM; D(+)glucose, 5.5 mM; HEPES acid, 3.07 mM; HEPES sodium salt, 1.9 mM [pH 7.40]). The left kidney was then removed for lectin staining (1/4 of the kidney, 4% PFA fixed) and glomerular permeability assay (3/4 of the same kidney, sieved for glomeruli) (<xref rid="B30" ref-type="bibr">30</xref>). The right kidney was subsequently perfusion fixed with a solution containing 2.5% glutaraldehyde, 0.1M cacodylate, and 1% Alcian blue for TEM to quantify GEnGlx thickness and coverage (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B46" ref-type="bibr">46</xref>).</p>
              </sec>
              <sec>
                <title>Glomerular albumin permeability (Ps’<sub>alb</sub>) assay.</title>
                <p>The glomerular P<italic toggle="yes">s’<sub>alb</sub></italic> assay was carried out as previously described (<xref rid="B30" ref-type="bibr">30</xref>). Briefly, Ringer-perfused kidney was sieved in 4% BSA in Ringer solution. Isolated glomeruli were incubated in 36.5 μg/mL octadecyl rhodamine B chloride (R18) (O246; Thermo Fisher Scientific) for 15 minutes and were then washed in 4% Ringer BSA to remove unbound R18, followed by 15 minutes’ incubation in 30 μg/mL Alexa Fluor 488–BSA (A13100; Thermo Fisher Scientific). An individual glomerulus was trapped on a custom-made petri dish, and the perfusate was switched from 30 μg/mL labeled 488-BSA to 30 μg/mL unlabeled BSA. A Nikon Ti-E inverted confocal microscope (Nikon Instruments Inc.) was used to capture the fluorescence intensity. The rate of decline in fluorescence intensity within the loop of the capillaries for the first minute was used to calculate P<italic toggle="yes">s’<sub>alb</sub></italic> as previously described (<xref rid="B30" ref-type="bibr">30</xref>). Observers were blinded to sample identity.</p>
              </sec>
              <sec>
                <title>Lectin staining.</title>
                <p>MOA, WGA, and UEA-I lectins have binding specificities for carbohydrate sequences present in the glycocalyx. MOA lectin binds to nonreducing terminal galactose-α-1,3-galactose-carbohydrates, WGA lectin binds to the sialyloligosaccharides, N-Acetylglucosamine and N-Acetylneuraminic acid, and UEA-I binds to α-L-fucose. Lectins were labeled with biotin or FlTC: biotinylated MOA (Z8-BA-9001-1, TCS Biosciences, 2 mg/mL; 1:100); FITC-WGA (GTX01502; GeneTex; 5 mg/mL; 1:500); and biotinylated UEA-I (GTX01511; GeneTex; 2 mg/mL; 1:200):</p>
                <p>Paraffin-embedded kidney sections (5 μm) were dewaxed in Histo-Clear II (National Diagnostics) followed by rehydration in graded ethanol and a wash in PBS. All sections were incubated in blocking buffer (1% BSA in PBS containing 0.1% Tween) for 30 minutes. For biotinylated lectins, this was followed by endogenous biotin blocking using a streptavidin/biotin blocking kit (SP-2002; Vector Laboratories). After 2 washes, the sections were incubated with the biotinylated lectin (pH 6.8) overnight at 4°C. Buffer only was used as a negative control. After 4 washes, the sections were incubated with streptavidin–Alexa Fluor 488 (1:500, S32354; Thermo Fisher Scientific) (pH 6.8) for 1 hour at room temperature. For FITC-labeled lectins, the sections were incubated overnight at 4°C (pH 6.8). Then, for all sections, the nuclei were counterstained with 4′,6-diamidino-2-phenylindole (D1306; Thermo Fisher Scientific) and the cell membrane was labeled with R18 (1:1,000, O246; Thermo Fisher Scientific) for 10 minutes at room temperature. After a 2-minute wash in PBS, the coverslips were mounted in Vectashield mounting medium (H-1000; Vector Laboratories) and examined using either an AF600 LX wide-field fluorescence microscope (Leica Microsystems) or a Leica SP5-II confocal laser scanning microscope attached to a Leica DMI 6000 inverted epifluorescence microscope.</p>
              </sec>
              <sec>
                <title>Fluorescent profile confocal peak-to-peak analysis.</title>
                <p>Initially, the fluorescence profile peak-to-peak assessment was carried out, blinded using a manual methodology, as previously described (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B50" ref-type="bibr">50</xref>). A perpendicular profile line (ROI in <xref rid="F2" ref-type="fig">Figure 2A</xref>) was drawn from the inside to the outside of the capillary loop crossing the lectin-labeled Glx first, followed by the R18 labeled endothelial membrane. Fluorescence intensity profiles were then generated for the lectin-labeled components of the EnGlx and endothelial cell label. The distance between the peak signals from the lectin-488 and the R18 labels (peak-to-peak) is an index of Glx thickness (<xref rid="F2" ref-type="fig">Figure 2B</xref>). The mean was determined from an average of 3 lines per capillary loop, 3 loops per glomerulus, and 3 glomeruli per rat. Our peak-to-peak measurement technique was subsequently updated to use a blinded automated methodology. This increased the number of measurements taken from each capillary loop and reduced the time taken to analyze each glomerulus. Briefly, we developed an ImageJ (NIH) macro to take multiple measurements in a preselected capillary loop and generate fluorescence intensity profiles for the lectin components of the GEnGlx and endothelial cell label. Gaussian curves were applied to the raw intensity data of each plot for peak-to-peak measurements (dashed lines in <xref rid="F2" ref-type="fig">Figure 2B</xref>). The mean was subsequently determined from 200 lines per capillary loop, 3 loops per glomerulus, and 4–6 glomeruli per rat. Data were excluded with a SD &gt; 7.5 and/or a signal-to-noise ratio &lt; 15.</p>
              </sec>
              <sec>
                <title>PAS staining.</title>
                <p>Rat paraffin-embedded kidney sections from perfused kidneys were stained using a periodic acid–Schiff (PAS) kit according to the manufacturer’s instructions. Images were quantified with ImageJ using the Haematoxylin PAS color deconvolution plug-in. Corrected total cell intensity values were calculated as follows: integrated density (area of glomerulus × background mean gray value). Ten glomeruli were analyzed per rat.</p>
              </sec>
              <sec>
                <title>TEM.</title>
                <p>Perfusion-fixed right kidneys were used for TEM, as described previously, to measure GEnC, GBM, and podocyte parameters to identify effects on GFB ultrastructure that could explain changes in glomerular permeability (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B46" ref-type="bibr">46</xref>). Electron micrographs were taken using a Technai 12 electron microscope (FEI), and image analysis was carried out using established protocols in 3–4 capillary loops per glomerulus and 2–3 glomeruli per animal (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B46" ref-type="bibr">46</xref>). Briefly, ImageJ (NIH) software (SciJava software ecosystem) was used to overlay a grid onto the electron micrograph. The anatomical distance from the luminal phospholipid at sequential grid intersections to the farthest point of the glycocalyx was measured as glycocalyx thickness. A glycocalyx thickness ≤ 10 nm was considered uncovered, and this was expressed as a percentage of total measurements taken on a grid section. GBM width, podocyte foot process width, and slit diaphragm width were also measured. Fenestration density and podocyte foot process density were measured by counting the number of each and dividing by the length of GBM used for analysis. Observers were blinded to sample identity.</p>
              </sec>
              <sec>
                <title>MMP activity.</title>
                <p>MMP2 activity was studied using the MMP2 Biotrack activity assay (RPN2631; GE Healthcare) and the SensoLyte Plus 520 MMP2 assay (AS-72224; AnaSpec). MMP9 activity was studied using the SensoLyte Plus 520 MMP9 assay (AS-72017; AnaSpec). The manufacturer’s instructions were followed in full. Urinary active MMP2 and MMP9 were normalized to creatinine. Glomerular active MMP2 and MMP9 were normalized to total protein using the Pierce BCA protein assay (23225; Thermo Fisher Scientific). The fold change relative to control was calculated to enable pooling of results from different experiments.</p>
              </sec>
              <sec>
                <title>Cell culture.</title>
                <p>Human CiGEnC (<xref rid="B106" ref-type="bibr">106</xref>) were maintained in EGM2 media (Lonza) supplemented with 10% FBS and EGM2-MV bullet kit (Lonza) in the absence of supplied gentamicin. Cells were differentiated at 37°C for 5 days (80% confluence) before entering the study and were free of mycoplasma infection. To mimic a diabetic environment in vitro, CiGEnC were maintained in the presence of 100 nmol/L insulin (Tocris), 25 mmol/L glucose (MilliporeSigma), 1 ng/mL TNF-α, and 1 ng/mL IL-6 (both from R&amp;D Systems) (<xref rid="B54" ref-type="bibr">54</xref>). To study alterations in gene expression, CiGEnC were pretreated for 2 hours with 0.1 μmol/L spironolactone (S3378; MilliporeSigma) or vehicle before 8 hours of exposure to DM conditions or mannitol (MilliporeSigma) (osmotic) control prior to mRNA harvest and cDNA conversion using standard techniques. Gene expression was determined using TaqMan Gene Expression Assays (Applied Biosystems) for <italic toggle="yes">MMP2</italic> (Hs01548727_m1), <italic toggle="yes">MMP9</italic> (Hs00957562_m1), and <italic toggle="yes">MMP14</italic> (Hs01037003_g1). The 2<sup>–ΔΔCT</sup> method of quantification was used to calculate the fold change, normalized to <italic toggle="yes">GAPDH</italic> (Hs02786624_g1). To study cell surface changes cells were pretreated with spironolactone or vehicle for 24 hours prior to 6 days exposure to DM conditions or osmotic control media, respectively. At the experimental end, cells were fixed (4% PFA) but not permeabilized prior to blocking with 1% BSA in PBS for 30 minutes and following a standard immunofluorescence protocol. Primary antibodies or WGA lectin were incubated overnight at 4°C (MMP2, 10373-2, Proteintech, 1:100; MMP9, AF909, R&amp;D Systems, 1:100; MMP14, EP1264Y, Abcam, 1:1,000; WGA, FITC-WGA, GTX01502, GeneTex, 5 mg/mL, 1:500). FITC-labeled secondary antibodies were incubated at room temperature for 2 hours. Negative controls were processed in the absence of the primary antibody and revealed no staining. The cell surface was imaged as previously using standardized settings. Florescence intensity was measured in randomly selected microscope fields (mean florescence intensity for cell covered area minus background intensity) by an observer in a blinded manner.</p>
              </sec>
              <sec>
                <title>Human renal samples.</title>
                <p>Renal biopsy samples from 34 patients were obtained from the Histopathology Department of Southmead Hospital (Bristol, United Kingdom) and Aldo Moro University of Bari (Division of Nephrology, Dialysis and Transplantation, Department of Emergency and Organ Transplantation; Bari, Italy). Tissue was immersion fixed in 10% neutral buffered formalin and embedded in paraffin. Samples had been clinicopathologically diagnosed, including 19 patients with DN, 8 patients with TBMN and 7 histologically normal control patients (<xref rid="T1" ref-type="table">Table 1</xref>). TBMN is the most common cause of persistent hematuria, and patients usually display minimal or no proteinuria, normal renal function, and a uniformly thinned GBM (<xref rid="B107" ref-type="bibr">107</xref>). TBMN occurs in more than 1% of the population and is considered a lifelong nonprogressive disorder (<xref rid="B108" ref-type="bibr">108</xref>). With limited numbers of histologically normal renal core biopsy samples available, we utilized samples from patients with TBMN to provide an additional comparison group.</p>
              </sec>
              <sec>
                <title>Human urine samples.</title>
                <p>Urine samples from 35 patients were obtained from a double-blind, placebo-controlled trial conducted in patients with diabetes as previously described (<xref rid="B57" ref-type="bibr">57</xref>). Briefly, the study population consisted of male and female subjects with type 1 or type 2 diabetes mellitus who satisfied the following criteria: (a) seated systolic BP &gt; 130 mmHg and albuminuria (uACR ≥ 300 mg/g); (b) all patients received the ACEi lisinopril (80 mg/day) and were randomly assigned to placebo or spironolactone (25 mg/day) for the 48 weeks; and (c) urine samples were obtained for baseline and 48-week measurements, from 20 placebo patients and 15 spironolactone patients (<xref rid="T2" ref-type="table">Table 2</xref>).</p>
              </sec>
              <sec>
                <title>Statistics.</title>
                <p>All statistics were calculated using Prism 8 (GraphPad). Normality was assessed visually and using the Shapiro-Wilk test. Where data was normally distributed, a 1-way ANOVA or Student’s 2-tailed <italic toggle="yes">t</italic> test was conducted. If data were not normally distributed, the nonparametric equivalents of these tests were used (Kruskal-Wallis 1-way ANOVA on ranks or Mann-Whitney rank-sum test) to establish if data were significant. The Tukey method (1-way ANOVA) or Dunn’s method (ranks) was used for multiple comparisons between groups. All data are expressed as mean ± SEM unless stated otherwise. Results with values of <italic toggle="yes">P</italic> &lt; 0.05 were considered statistically significant. Individual rats were considered experimental units within this study.</p>
              </sec>
              <sec>
                <title>Study approval.</title>
                <p>All animal protocols were approved by the UK Government Home Office and conformed to the <italic toggle="yes">Guide for the Care and Use of Laboratory Animals</italic> (National Academies Press, 2011). All human studies were approved by national and local research ethics committees (REC) and conducted in accordance with the tenets of the Declaration of Helsinki. Human renal samples provided from Bristol were archived anonymized samples (REC H0102/45). For renal samples provided from Bari, Italy, patients gave written informed consent for the use of this material for research purposes (Prot. N.4104/2013). Human urine samples were obtained from a double-blind, placebo-controlled trial conducted in patients with diabetes; this study was approved by the UT Southwestern Medical Center IRB (ClinicalTrials.gov; NCT00381134).</p>
              </sec>
            </sec>
            <sec>
              <title>Author contributions</title>
              <p>MC, GIW, RRF, SCS, and MJB designed research; MC, JKF, RDR, ASO, LKD, and MJB performed research; JS, CJD, SJH, PP, LG, HLH, and RDT contributed resources; MC, JKF, KLO, ASO, MG, LS, KHW, and MJB analyzed data; MC, SCS, and MJB wrote paper; and all authors approved the final version of the manuscript.</p>
            </sec>
            <sec sec-type="supplementary-material" id="sd">
              <title>Supplementary Material</title>
              <supplementary-material id="SD1" position="float" content-type="local-data">
                <caption>
                  <title>Supplemental data</title>
                </caption>
                <media xlink:href="jciinsight-8-154164-s198.pdf" id="d64e1211" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>The authors would like to thank the Medical Research Council in addition to the Wolfson Foundation for establishing the Wolfson Bioimaging Facility and gratefully acknowledge the Wolfson Bioimaging Facility for their support and assistance in this work. Specifically, we thank Stephen Cross for helping to develop our automated peak-to-peak methodology. Kidney Research UK grants (RP_031_20180306, JF-S/RP/2015/10, RP_002_20190917, ID_004_20170330, and IN_004_20190305); a Diabetes UK grant (18/0005795); a British Heart Foundation grant (PG/15/81/31740); and a Medical Research Council Clinical Research Training Fellowship grant (MR/M018237/1 for MJB) also funded this work. PP, LG, HLH, and SCS are members of the Biomarker Enterprise to Attack Diabetic Kidney Disease (BEAt-DKD) consortium; this project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115974. The joint undertaking (JU) receives support from the European Union’s Horizon 2020 research and innovation programme and European federation of Pharmaceutical Industries and Associations (EFPIA) and Juvenile Diabetes Research Foundation (JDRF). Any dissemination of results reflects only the author’s view; the JU is not responsible for any use that may be made of the information it contains.</p>
            </ack>
            <fn-group>
              <fn>
                <p><bold>Conflict of interest:</bold> The authors have declared that no conflict of interest exists.</p>
              </fn>
              <fn>
                <p><bold>Copyright:</bold> © 2023, Crompton et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.</p>
              </fn>
              <fn>
                <p><bold>Reference information:</bold><italic toggle="yes"> JCI Insight</italic>. 2023;8(5):e154164.https://doi.org/10.1172/jci.insight.154164.</p>
              </fn>
            </fn-group>
            <ref-list>
              <ref id="B1">
                <label>1</label>
                <element-citation publication-type="webpage" publication-format="online">
                  <comment>UK Renal Registry. UK Renal Registry 22nd Annual Report – Data to 31/12/2018. <ext-link xlink:href="https://ukkidney.org/sites/renal.org/files/publication/file-attachments/22nd_UKRR_ANNUAL_REPORT_FULL.pdf" ext-link-type="uri">https://ukkidney.org/sites/renal.org/files/publication/file-attachments/22nd_UKRR_ANNUAL_REPORT_FULL.pdf</ext-link> Accessed January 25, 2023</comment>
                </element-citation>
              </ref>
              <ref id="B2">
                <label>2</label>
                <element-citation publication-type="webpage" publication-format="online">
                  <comment>NHS Digital. National Diabetes Audit, 2015-16 Report 2a: Complications and Mortality. Available from. <ext-link xlink:href="https://www.hqip.org.uk/wp-content/uploads/2018/02/TIwCJZ.pdf" ext-link-type="uri">https://www.hqip.org.uk/wp-content/uploads/2018/02/TIwCJZ.pdf</ext-link> Accessed January 25, 2023</comment>
                </element-citation>
              </ref>
              <ref id="B3">
                <label>3</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Johansen</surname>
                      <given-names>KL</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>US Renal Data System 2020 annual data report: epidemiology of kidney disease in the United States</article-title>
                  <source>Am J Kidney Dis</source>
                  <year>2021</year>
                  <volume>77</volume>
                  <issue>4 suppl 1</issue>
                  <fpage>A7</fpage>
                  <lpage>A8</lpage>
                  <!--<pub-id pub-id-type="pmcid">8148988</pub-id>-->
                  <?supplied-pmid 33752804?>
                  <pub-id pub-id-type="pmid">33752804</pub-id>
                </element-citation>
              </ref>
              <ref id="B4">
                <label>4</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Strippoli</surname>
                      <given-names>GF</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease</article-title>
                  <source>Cochrane Database Syst Rev</source>
                  <year>2006</year>
                  <volume>2006</volume>
                  <issue>4</issue>
                  <elocation-id>CD006257</elocation-id>
                  <!--<pub-id pub-id-type="pmcid">6956646</pub-id>-->
                  <?supplied-pmid 17054288?>
                  <pub-id pub-id-type="pmid">17054288</pub-id>
                </element-citation>
              </ref>
              <ref id="B5">
                <label>5</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Staessen</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Rise in plasma concentration of aldosterone during long-term angiotensin II suppression</article-title>
                  <source>J Endocrinol</source>
                  <year>1981</year>
                  <volume>91</volume>
                  <issue>3</issue>
                  <fpage>457</fpage>
                  <lpage>465</lpage>
                  <pub-id pub-id-type="doi">10.1677/joe.0.0910457</pub-id>
                  <?supplied-pmid 7035596?>
                  <pub-id pub-id-type="pmid">7035596</pub-id>
                </element-citation>
              </ref>
              <ref id="B6">
                <label>6</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schjoedt</surname>
                      <given-names>KJ</given-names>
                    </name>
                  </person-group>
                  <article-title>The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone</article-title>
                  <source>Dan Med Bull</source>
                  <year>2011</year>
                  <volume>58</volume>
                  <issue>4</issue>
                  <elocation-id>B4265</elocation-id>
                  <?supplied-pmid 21466768?>
                  <pub-id pub-id-type="pmid">21466768</pub-id>
                </element-citation>
              </ref>
              <ref id="B7">
                <label>7</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mavrakanas</surname>
                      <given-names>TA</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review</article-title>
                  <source>Eur J Intern Med</source>
                  <year>2014</year>
                  <volume>25</volume>
                  <issue>2</issue>
                  <fpage>173</fpage>
                  <lpage>176</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ejim.2013.11.007</pub-id>
                  <?supplied-pmid 24315413?>
                  <pub-id pub-id-type="pmid">24315413</pub-id>
                </element-citation>
              </ref>
              <ref id="B8">
                <label>8</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sato</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Effectiveness of aldosterone blockade in patients with diabetic nephropathy</article-title>
                  <source>Hypertension</source>
                  <year>2003</year>
                  <volume>41</volume>
                  <issue>1</issue>
                  <fpage>64</fpage>
                  <lpage>68</lpage>
                  <pub-id pub-id-type="doi">10.1161/01.HYP.0000044937.95080.E9</pub-id>
                  <?supplied-pmid 12511531?>
                  <pub-id pub-id-type="pmid">12511531</pub-id>
                </element-citation>
              </ref>
              <ref id="B9">
                <label>9</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sato</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease</article-title>
                  <source>Am J Hypertens</source>
                  <year>2005</year>
                  <volume>18</volume>
                  <issue>1</issue>
                  <fpage>44</fpage>
                  <lpage>49</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.amjhyper.2004.06.029</pub-id>
                  <?supplied-pmid 15691616?>
                  <pub-id pub-id-type="pmid">15691616</pub-id>
                </element-citation>
              </ref>
              <ref id="B10">
                <label>10</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sun</surname>
                      <given-names>L-J</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy</article-title>
                  <source>J Diabetes Investig</source>
                  <year>2017</year>
                  <volume>8</volume>
                  <issue>4</issue>
                  <fpage>609</fpage>
                  <lpage>618</lpage>
                  <pub-id pub-id-type="doi">10.1111/jdi.12629</pub-id>
                  <!--<pub-id pub-id-type="pmcid">5497036</pub-id>-->
                  <?supplied-pmid 28107779?>
                  <pub-id pub-id-type="pmid">28107779</pub-id>
                </element-citation>
              </ref>
              <ref id="B11">
                <label>11</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bianchi</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease</article-title>
                  <source>Kidney Int</source>
                  <year>2006</year>
                  <volume>70</volume>
                  <issue>12</issue>
                  <fpage>2116</fpage>
                  <lpage>2123</lpage>
                  <pub-id pub-id-type="doi">10.1038/sj.ki.5001854</pub-id>
                  <?supplied-pmid 17035949?>
                  <pub-id pub-id-type="pmid">17035949</pub-id>
                </element-citation>
              </ref>
              <ref id="B12">
                <label>12</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Navaneethan</surname>
                      <given-names>SD</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis</article-title>
                  <source>Clin J Am Soc Nephrol</source>
                  <year>2009</year>
                  <volume>4</volume>
                  <issue>3</issue>
                  <fpage>542</fpage>
                  <lpage>551</lpage>
                  <pub-id pub-id-type="doi">10.2215/CJN.04750908</pub-id>
                  <!--<pub-id pub-id-type="pmcid">2653663</pub-id>-->
                  <?supplied-pmid 19261819?>
                  <pub-id pub-id-type="pmid">19261819</pub-id>
                </element-citation>
              </ref>
              <ref id="B13">
                <label>13</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bakris</surname>
                      <given-names>GL</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes</article-title>
                  <source>N Engl J Med</source>
                  <year>2020</year>
                  <volume>383</volume>
                  <issue>23</issue>
                  <fpage>2219</fpage>
                  <lpage>2229</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa2025845</pub-id>
                  <?supplied-pmid 33264825?>
                  <pub-id pub-id-type="pmid">33264825</pub-id>
                </element-citation>
              </ref>
              <ref id="B14">
                <label>14</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pitt</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Rossignol</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Mineralocorticoid receptor antagonists in patients with end-stage renal disease on chronic hemodialysis</article-title>
                  <source>J Am Coll Cardiol</source>
                  <year>2014</year>
                  <volume>63</volume>
                  <issue>6</issue>
                  <fpage>537</fpage>
                  <lpage>538</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jacc.2013.09.057</pub-id>
                  <?supplied-pmid 24184253?>
                  <pub-id pub-id-type="pmid">24184253</pub-id>
                </element-citation>
              </ref>
              <ref id="B15">
                <label>15</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ng</surname>
                      <given-names>KP</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Results and lessons from the spironolactone to prevent cardiovascular events in early stage chronic kidney disease (STOP-CKD) randomised controlled trial</article-title>
                  <source>BMJ Open</source>
                  <year>2016</year>
                  <volume>6</volume>
                  <issue>2</issue>
                  <elocation-id>e010519</elocation-id>
                  <pub-id pub-id-type="doi">10.1136/bmjopen-2015-010519</pub-id>
                  <!--<pub-id pub-id-type="pmcid">4769397</pub-id>-->
                  <?supplied-pmid 26916697?>
                  <pub-id pub-id-type="pmid">26916697</pub-id>
                </element-citation>
              </ref>
              <ref id="B16">
                <label>16</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Currie</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis</article-title>
                  <source>BMC Nephrol</source>
                  <year>2016</year>
                  <volume>17</volume>
                  <issue>1</issue>
                  <elocation-id>127</elocation-id>
                  <pub-id pub-id-type="doi">10.1186/s12882-016-0337-0</pub-id>
                  <!--<pub-id pub-id-type="pmcid">5015203</pub-id>-->
                  <?supplied-pmid 27609359?>
                  <pub-id pub-id-type="pmid">27609359</pub-id>
                </element-citation>
              </ref>
              <ref id="B17">
                <label>17</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Caprio</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion</article-title>
                  <source>Circ Res</source>
                  <year>2008</year>
                  <volume>102</volume>
                  <issue>11</issue>
                  <fpage>1359</fpage>
                  <lpage>1367</lpage>
                  <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.174235</pub-id>
                  <!--<pub-id pub-id-type="pmcid">2597516</pub-id>-->
                  <?supplied-pmid 18467630?>
                  <pub-id pub-id-type="pmid">18467630</pub-id>
                </element-citation>
              </ref>
              <ref id="B18">
                <label>18</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McCurley</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Jaffe</surname>
                      <given-names>IZ</given-names>
                    </name>
                  </person-group>
                  <article-title>Mineralocorticoid receptors in vascular function and disease</article-title>
                  <source>Mol Cell Endocrinol</source>
                  <year>2012</year>
                  <volume>350</volume>
                  <issue>2</issue>
                  <fpage>256</fpage>
                  <lpage>265</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.mce.2011.06.014</pub-id>
                  <pub-id pub-id-type="pmid">21723914</pub-id>
                </element-citation>
              </ref>
              <ref id="B19">
                <label>19</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Butler</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Aldosterone induces albuminuria via matrix metalloproteinase-dependent damage of the endothelial glycocalyx</article-title>
                  <source>Kidney Int</source>
                  <year>2019</year>
                  <volume>95</volume>
                  <issue>1</issue>
                  <fpage>94</fpage>
                  <lpage>107</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.kint.2018.08.024</pub-id>
                  <!--<pub-id pub-id-type="pmcid">6506575</pub-id>-->
                  <?supplied-pmid 30389198?>
                  <pub-id pub-id-type="pmid">30389198</pub-id>
                </element-citation>
              </ref>
              <ref id="B20">
                <label>20</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Satchell</surname>
                      <given-names>SC</given-names>
                    </name>
                  </person-group>
                  <article-title>The glomerular endothelium emerges as a key player in diabetic nephropathy</article-title>
                  <source>Kidney Int</source>
                  <year>2012</year>
                  <volume>82</volume>
                  <issue>9</issue>
                  <fpage>949</fpage>
                  <lpage>951</lpage>
                  <pub-id pub-id-type="doi">10.1038/ki.2012.258</pub-id>
                  <?supplied-pmid 23064188?>
                  <pub-id pub-id-type="pmid">23064188</pub-id>
                </element-citation>
              </ref>
              <ref id="B21">
                <label>21</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Haraldsson</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Properties of the glomerular barrier and mechanisms of proteinuria</article-title>
                  <source>Physiol Rev</source>
                  <year>2008</year>
                  <volume>88</volume>
                  <issue>2</issue>
                  <fpage>451</fpage>
                  <lpage>487</lpage>
                  <pub-id pub-id-type="doi">10.1152/physrev.00055.2006</pub-id>
                  <?supplied-pmid 18391170?>
                  <pub-id pub-id-type="pmid">18391170</pub-id>
                </element-citation>
              </ref>
              <ref id="B22">
                <label>22</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Salmon</surname>
                      <given-names>AHJ</given-names>
                    </name>
                    <name>
                      <surname>Satchell</surname>
                      <given-names>SC</given-names>
                    </name>
                  </person-group>
                  <article-title>Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability</article-title>
                  <source>J Pathol</source>
                  <year>2012</year>
                  <volume>226</volume>
                  <issue>4</issue>
                  <fpage>562</fpage>
                  <lpage>574</lpage>
                  <pub-id pub-id-type="doi">10.1002/path.3964</pub-id>
                  <?supplied-pmid 22102407?>
                  <pub-id pub-id-type="pmid">22102407</pub-id>
                </element-citation>
              </ref>
              <ref id="B23">
                <label>23</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Satchell</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>The role of the glomerular endothelium in albumin handling</article-title>
                  <source>Nat Rev Nephrol</source>
                  <year>2013</year>
                  <volume>9</volume>
                  <issue>12</issue>
                  <fpage>717</fpage>
                  <lpage>725</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrneph.2013.197</pub-id>
                  <?supplied-pmid 24080802?>
                  <pub-id pub-id-type="pmid">24080802</pub-id>
                </element-citation>
              </ref>
              <ref id="B24">
                <label>24</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Singh</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>High glucose causes dysfunction of the human glomerular endothelial glycocalyx</article-title>
                  <source>Am J Physiol Renal Physiol</source>
                  <year>2011</year>
                  <volume>300</volume>
                  <issue>1</issue>
                  <fpage>F40</fpage>
                  <lpage>F48</lpage>
                  <pub-id pub-id-type="doi">10.1152/ajprenal.00103.2010</pub-id>
                  <!--<pub-id pub-id-type="pmcid">3023224</pub-id>-->
                  <?supplied-pmid 20980411?>
                  <pub-id pub-id-type="pmid">20980411</pub-id>
                </element-citation>
              </ref>
              <ref id="B25">
                <label>25</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Singh</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Reactive oxygen species modulate the barrier function of the human glomerular endothelial glycocalyx</article-title>
                  <source>PLoS One</source>
                  <year>2013</year>
                  <volume>8</volume>
                  <issue>2</issue>
                  <elocation-id>e55852</elocation-id>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0055852</pub-id>
                  <!--<pub-id pub-id-type="pmcid">3573029</pub-id>-->
                  <?supplied-pmid 23457483?>
                  <pub-id pub-id-type="pmid">23457483</pub-id>
                </element-citation>
              </ref>
              <ref id="B26">
                <label>26</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Singh</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Glomerular endothelial glycocalyx constitutes a barrier to protein permeability</article-title>
                  <source>J Am Soc Nephrol</source>
                  <year>2007</year>
                  <volume>18</volume>
                  <issue>11</issue>
                  <fpage>2885</fpage>
                  <lpage>2893</lpage>
                  <pub-id pub-id-type="doi">10.1681/ASN.2007010119</pub-id>
                  <?supplied-pmid 17942961?>
                  <pub-id pub-id-type="pmid">17942961</pub-id>
                </element-citation>
              </ref>
              <ref id="B27">
                <label>27</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jeansson</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Haraldsson</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier</article-title>
                  <source>Am J Physiol Renal Physiol</source>
                  <year>2006</year>
                  <volume>290</volume>
                  <issue>1</issue>
                  <fpage>F111</fpage>
                  <lpage>F116</lpage>
                  <pub-id pub-id-type="doi">10.1152/ajprenal.00173.2005</pub-id>
                  <?supplied-pmid 16091582?>
                  <pub-id pub-id-type="pmid">16091582</pub-id>
                </element-citation>
              </ref>
              <ref id="B28">
                <label>28</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Salmon</surname>
                      <given-names>AHJ</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction</article-title>
                  <source>J Am Soc Nephrol</source>
                  <year>2012</year>
                  <volume>23</volume>
                  <issue>8</issue>
                  <fpage>1339</fpage>
                  <lpage>1350</lpage>
                  <pub-id pub-id-type="doi">10.1681/ASN.2012010017</pub-id>
                  <!--<pub-id pub-id-type="pmcid">3402289</pub-id>-->
                  <?supplied-pmid 22797190?>
                  <pub-id pub-id-type="pmid">22797190</pub-id>
                </element-citation>
              </ref>
              <ref id="B29">
                <label>29</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jeansson</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Haraldsson</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Glomerular size and charge selectivity in the mouse after exposure to glucosaminoglycan-degrading enzymes</article-title>
                  <source>J Am Soc Nephrol</source>
                  <year>2003</year>
                  <volume>14</volume>
                  <issue>7</issue>
                  <fpage>1756</fpage>
                  <lpage>1765</lpage>
                  <pub-id pub-id-type="doi">10.1097/01.ASN.0000072742.02714.6E</pub-id>
                  <?supplied-pmid 12819235?>
                  <pub-id pub-id-type="pmid">12819235</pub-id>
                </element-citation>
              </ref>
              <ref id="B30">
                <label>30</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Desideri</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>A novel assay provides sensitive measurement of physiologically relevant changes in albumin permeability in isolated human and rodent glomeruli</article-title>
                  <source>Kidney Int</source>
                  <year>2018</year>
                  <volume>93</volume>
                  <issue>5</issue>
                  <fpage>1086</fpage>
                  <lpage>1097</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.kint.2017.12.003</pub-id>
                  <!--<pub-id pub-id-type="pmcid">5912930</pub-id>-->
                  <?supplied-pmid 29433915?>
                  <pub-id pub-id-type="pmid">29433915</pub-id>
                </element-citation>
              </ref>
              <ref id="B31">
                <label>31</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Reitsma</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The endothelial glycocalyx: composition, functions, and visualization</article-title>
                  <source>Pflugers Arch</source>
                  <year>2007</year>
                  <volume>454</volume>
                  <issue>3</issue>
                  <fpage>345</fpage>
                  <lpage>359</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00424-007-0212-8</pub-id>
                  <!--<pub-id pub-id-type="pmcid">1915585</pub-id>-->
                  <?supplied-pmid 17256154?>
                  <pub-id pub-id-type="pmid">17256154</pub-id>
                </element-citation>
              </ref>
              <ref id="B32">
                <label>32</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Henry</surname>
                      <given-names>CB</given-names>
                    </name>
                    <name>
                      <surname>Duling</surname>
                      <given-names>BR</given-names>
                    </name>
                  </person-group>
                  <article-title>Permeation of the luminal capillary glycocalyx is determined by hyaluronan</article-title>
                  <source>Am J Physiol</source>
                  <year>1999</year>
                  <volume>277</volume>
                  <issue>2</issue>
                  <fpage>H508</fpage>
                  <lpage>H514</lpage>
                  <?supplied-pmid 10444475?>
                  <pub-id pub-id-type="pmid">10444475</pub-id>
                </element-citation>
              </ref>
              <ref id="B33">
                <label>33</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vink</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Duling</surname>
                      <given-names>BR</given-names>
                    </name>
                  </person-group>
                  <article-title>Capillary endothelial surface layer selectively reduces plasma solute distribution volume</article-title>
                  <source>Am J Physiol Heart Circ Physiol</source>
                  <year>2000</year>
                  <volume>278</volume>
                  <issue>1</issue>
                  <fpage>H285</fpage>
                  <lpage>H289</lpage>
                  <pub-id pub-id-type="doi">10.1152/ajpheart.2000.278.1.H285</pub-id>
                  <?supplied-pmid 10644610?>
                  <pub-id pub-id-type="pmid">10644610</pub-id>
                </element-citation>
              </ref>
              <ref id="B34">
                <label>34</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Davies</surname>
                      <given-names>PF</given-names>
                    </name>
                  </person-group>
                  <article-title>Flow-mediated endothelial mechanotransduction</article-title>
                  <source>Physiol Rev</source>
                  <year>1995</year>
                  <volume>75</volume>
                  <issue>3</issue>
                  <fpage>519</fpage>
                  <lpage>560</lpage>
                  <pub-id pub-id-type="doi">10.1152/physrev.1995.75.3.519</pub-id>
                  <pub-id pub-id-type="pmid">7624393</pub-id>
                </element-citation>
              </ref>
              <ref id="B35">
                <label>35</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dewey</surname>
                      <given-names>CF</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The dynamic response of vascular endothelial cells to fluid shear stress</article-title>
                  <source>J Biomech Eng</source>
                  <year>1981</year>
                  <volume>103</volume>
                  <issue>3</issue>
                  <fpage>177</fpage>
                  <lpage>185</lpage>
                  <pub-id pub-id-type="doi">10.1115/1.3138276</pub-id>
                  <?supplied-pmid 7278196?>
                  <pub-id pub-id-type="pmid">7278196</pub-id>
                </element-citation>
              </ref>
              <ref id="B36">
                <label>36</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vink</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Duling</surname>
                      <given-names>BR</given-names>
                    </name>
                  </person-group>
                  <article-title>Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries</article-title>
                  <source>Circ Res</source>
                  <year>1996</year>
                  <volume>79</volume>
                  <issue>3</issue>
                  <fpage>581</fpage>
                  <lpage>589</lpage>
                  <pub-id pub-id-type="doi">10.1161/01.RES.79.3.581</pub-id>
                  <?supplied-pmid 8781491?>
                  <pub-id pub-id-type="pmid">8781491</pub-id>
                </element-citation>
              </ref>
              <ref id="B37">
                <label>37</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vink</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Oxidized lipoproteins degrade the endothelial surface layer : implications for platelet-endothelial cell adhesion</article-title>
                  <source>Circulation</source>
                  <year>2000</year>
                  <volume>101</volume>
                  <issue>13</issue>
                  <fpage>1500</fpage>
                  <lpage>1502</lpage>
                  <pub-id pub-id-type="doi">10.1161/01.CIR.101.13.1500</pub-id>
                  <?supplied-pmid 10747340?>
                  <pub-id pub-id-type="pmid">10747340</pub-id>
                </element-citation>
              </ref>
              <ref id="B38">
                <label>38</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yilmaz</surname>
                      <given-names>O</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The role of endothelial glycocalyx in health and disease</article-title>
                  <source>Clin Kidney J</source>
                  <year>2019</year>
                  <volume>12</volume>
                  <issue>5</issue>
                  <fpage>611</fpage>
                  <lpage>619</lpage>
                  <pub-id pub-id-type="doi">10.1093/ckj/sfz042</pub-id>
                  <!--<pub-id pub-id-type="pmcid">6768294</pub-id>-->
                  <?supplied-pmid 31583086?>
                  <pub-id pub-id-type="pmid">31583086</pub-id>
                </element-citation>
              </ref>
              <ref id="B39">
                <label>39</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Weinbaum</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The structure and function of the endothelial glycocalyx layer</article-title>
                  <source>Annu Rev Biomed Eng</source>
                  <year>2007</year>
                  <volume>9</volume>
                  <fpage>121</fpage>
                  <lpage>167</lpage>
                  <pub-id pub-id-type="doi">10.1146/annurev.bioeng.9.060906.151959</pub-id>
                  <?supplied-pmid 17373886?>
                  <pub-id pub-id-type="pmid">17373886</pub-id>
                </element-citation>
              </ref>
              <ref id="B40">
                <label>40</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Butler</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The pathological relevance of increased endothelial glycocalyx permeability</article-title>
                  <source>Am J Pathol</source>
                  <year>2020</year>
                  <volume>190</volume>
                  <issue>4</issue>
                  <fpage>742</fpage>
                  <lpage>751</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ajpath.2019.11.015</pub-id>
                  <!--<pub-id pub-id-type="pmcid">7163249</pub-id>-->
                  <?supplied-pmid 32035881?>
                  <pub-id pub-id-type="pmid">32035881</pub-id>
                </element-citation>
              </ref>
              <ref id="B41">
                <label>41</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Satchell</surname>
                      <given-names>SC</given-names>
                    </name>
                    <name>
                      <surname>Tooke</surname>
                      <given-names>JE</given-names>
                    </name>
                  </person-group>
                  <article-title>What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?</article-title>
                  <source>Diabetologia</source>
                  <year>2008</year>
                  <volume>51</volume>
                  <issue>5</issue>
                  <fpage>714</fpage>
                  <lpage>725</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00125-008-0961-8</pub-id>
                  <!--<pub-id pub-id-type="pmcid">2292427</pub-id>-->
                  <?supplied-pmid 18347777?>
                  <pub-id pub-id-type="pmid">18347777</pub-id>
                </element-citation>
              </ref>
              <ref id="B42">
                <label>42</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nieuwdorp</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes</article-title>
                  <source>Diabetes</source>
                  <year>2006</year>
                  <volume>55</volume>
                  <issue>4</issue>
                  <fpage>1127</fpage>
                  <lpage>1132</lpage>
                  <pub-id pub-id-type="doi">10.2337/diabetes.55.04.06.db05-1619</pub-id>
                  <?supplied-pmid 16567538?>
                  <pub-id pub-id-type="pmid">16567538</pub-id>
                </element-citation>
              </ref>
              <ref id="B43">
                <label>43</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Broekhuizen</surname>
                      <given-names>LN</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus</article-title>
                  <source>Diabetologia</source>
                  <year>2010</year>
                  <volume>53</volume>
                  <issue>12</issue>
                  <fpage>2646</fpage>
                  <lpage>2655</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00125-010-1910-x</pub-id>
                  <!--<pub-id pub-id-type="pmcid">2974920</pub-id>-->
                  <?supplied-pmid 20865240?>
                  <pub-id pub-id-type="pmid">20865240</pub-id>
                </element-citation>
              </ref>
              <ref id="B44">
                <label>44</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Satoh</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>In vivo visualization of glomerular microcirculation and hyperfiltration in streptozotocin-induced diabetic rats</article-title>
                  <source>Microcirculation</source>
                  <year>2010</year>
                  <volume>17</volume>
                  <issue>2</issue>
                  <fpage>103</fpage>
                  <lpage>112</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1549-8719.2009.00010.x</pub-id>
                  <?supplied-pmid 20163537?>
                  <pub-id pub-id-type="pmid">20163537</pub-id>
                </element-citation>
              </ref>
              <ref id="B45">
                <label>45</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jeansson</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Functional and molecular alterations of the glomerular barrier in long-term diabetes in mice</article-title>
                  <source>Diabetologia</source>
                  <year>2006</year>
                  <volume>49</volume>
                  <issue>9</issue>
                  <fpage>2200</fpage>
                  <lpage>2209</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00125-006-0319-z</pub-id>
                  <?supplied-pmid 16868749?>
                  <pub-id pub-id-type="pmid">16868749</pub-id>
                </element-citation>
              </ref>
              <ref id="B46">
                <label>46</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Oltean</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy</article-title>
                  <source>J Am Soc Nephrol</source>
                  <year>2015</year>
                  <volume>26</volume>
                  <issue>8</issue>
                  <fpage>1889</fpage>
                  <lpage>1904</lpage>
                  <pub-id pub-id-type="doi">10.1681/ASN.2014040350</pub-id>
                  <!--<pub-id pub-id-type="pmcid">4520162</pub-id>-->
                  <?supplied-pmid 25542969?>
                  <pub-id pub-id-type="pmid">25542969</pub-id>
                </element-citation>
              </ref>
              <ref id="B47">
                <label>47</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ramnath</surname>
                      <given-names>RD</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Blocking matrix metalloproteinase-mediated syndecan-4 shedding restores the endothelial glycocalyx and glomerular filtration barrier function in early diabetic kidney disease</article-title>
                  <source>Kidney Int</source>
                  <year>2020</year>
                  <volume>97</volume>
                  <issue>5</issue>
                  <fpage>951</fpage>
                  <lpage>965</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.kint.2019.09.035</pub-id>
                  <!--<pub-id pub-id-type="pmcid">7184681</pub-id>-->
                  <?supplied-pmid 32037077?>
                  <pub-id pub-id-type="pmid">32037077</pub-id>
                </element-citation>
              </ref>
              <ref id="B48">
                <label>48</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Manon-Jensen</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Proteoglycans in health and disease: the multiple roles of syndecan shedding</article-title>
                  <source>FEBS J</source>
                  <year>2010</year>
                  <volume>277</volume>
                  <issue>19</issue>
                  <fpage>3876</fpage>
                  <lpage>3889</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1742-4658.2010.07798.x</pub-id>
                  <pub-id pub-id-type="pmid">20840585</pub-id>
                </element-citation>
              </ref>
              <ref id="B49">
                <label>49</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ramnath</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Matrix metalloproteinase 9-mediated shedding of syndecan 4 in response to tumor necrosis factor α: a contributor to endothelial cell glycocalyx dysfunction</article-title>
                  <source>FASEB J</source>
                  <year>2014</year>
                  <volume>28</volume>
                  <issue>11</issue>
                  <fpage>4686</fpage>
                  <lpage>4699</lpage>
                  <pub-id pub-id-type="pmid">25122554</pub-id>
                </element-citation>
              </ref>
              <ref id="B50">
                <label>50</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Betteridge</surname>
                      <given-names>KB</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Sialic acids regulate microvessel permeability, revealed by novel in vivo studies of endothelial glycocalyx structure and function</article-title>
                  <source>J Physiol</source>
                  <year>2017</year>
                  <volume>595</volume>
                  <issue>15</issue>
                  <fpage>5015</fpage>
                  <lpage>5035</lpage>
                  <pub-id pub-id-type="doi">10.1113/JP274167</pub-id>
                  <!--<pub-id pub-id-type="pmcid">5538239</pub-id>-->
                  <?supplied-pmid 28524373?>
                  <pub-id pub-id-type="pmid">28524373</pub-id>
                </element-citation>
              </ref>
              <ref id="B51">
                <label>51</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Li</surname>
                      <given-names>Z</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Activation of MMP-9 by membrane type-1 MMP/MMP-2 axis stimulates tumor metastasis</article-title>
                  <source>Cancer Sci</source>
                  <year>2017</year>
                  <volume>108</volume>
                  <issue>3</issue>
                  <fpage>347</fpage>
                  <lpage>353</lpage>
                  <pub-id pub-id-type="doi">10.1111/cas.13134</pub-id>
                  <!--<pub-id pub-id-type="pmcid">5378257</pub-id>-->
                  <?supplied-pmid 27987367?>
                  <pub-id pub-id-type="pmid">27987367</pub-id>
                </element-citation>
              </ref>
              <ref id="B52">
                <label>52</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Têtu</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis</article-title>
                  <source>Breast Cancer Res</source>
                  <year>2006</year>
                  <volume>8</volume>
                  <issue>3</issue>
                  <elocation-id>R28</elocation-id>
                  <pub-id pub-id-type="doi">10.1186/bcr1503</pub-id>
                  <!--<pub-id pub-id-type="pmcid">1557730</pub-id>-->
                  <?supplied-pmid 16776850?>
                  <pub-id pub-id-type="pmid">16776850</pub-id>
                </element-citation>
              </ref>
              <ref id="B53">
                <label>53</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hernández-Pérez</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Expression of gelatinases (MMP-2, MMP-9) and gelatinase activator (MMP-14) in actinic keratosis and in in situ and invasive squamous cell carcinoma</article-title>
                  <source>Am J Dermatopathol</source>
                  <year>2012</year>
                  <volume>34</volume>
                  <issue>7</issue>
                  <fpage>723</fpage>
                  <lpage>728</lpage>
                  <pub-id pub-id-type="doi">10.1097/DAD.0b013e31824b1ddf</pub-id>
                  <?supplied-pmid 22534634?>
                  <pub-id pub-id-type="pmid">22534634</pub-id>
                </element-citation>
              </ref>
              <ref id="B54">
                <label>54</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lay</surname>
                      <given-names>AC</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Prolonged exposure of mouse and human podocytes to insulin induces insulin resistance through lysosomal and proteasomal degradation of the insulin receptor</article-title>
                  <source>Diabetologia</source>
                  <year>2017</year>
                  <volume>60</volume>
                  <issue>11</issue>
                  <fpage>2299</fpage>
                  <lpage>2311</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00125-017-4394-0</pub-id>
                  <!--<pub-id pub-id-type="pmcid">6448913</pub-id>-->
                  <?supplied-pmid 28852804?>
                  <pub-id pub-id-type="pmid">28852804</pub-id>
                </element-citation>
              </ref>
              <ref id="B55">
                <label>55</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Holthöfer</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Ulex europaeus I lectin as a marker for vascular endothelium in human tissues</article-title>
                  <source>Lab Invest</source>
                  <year>1982</year>
                  <volume>47</volume>
                  <issue>1</issue>
                  <fpage>60</fpage>
                  <lpage>66</lpage>
                  <?supplied-pmid 6177923?>
                  <pub-id pub-id-type="pmid">6177923</pub-id>
                </element-citation>
              </ref>
              <ref id="B56">
                <label>56</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Miettinen</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Ulex europaeus I lectin as a marker for tumors derived from endothelial cells</article-title>
                  <source>Am J Clin Pathol</source>
                  <year>1983</year>
                  <volume>79</volume>
                  <issue>1</issue>
                  <fpage>32</fpage>
                  <lpage>36</lpage>
                  <pub-id pub-id-type="doi">10.1093/ajcp/79.1.32</pub-id>
                  <?supplied-pmid 6401381?>
                  <pub-id pub-id-type="pmid">6401381</pub-id>
                </element-citation>
              </ref>
              <ref id="B57">
                <label>57</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mehdi</surname>
                      <given-names>UF</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy</article-title>
                  <source>J Am Soc Nephrol</source>
                  <year>2009</year>
                  <volume>20</volume>
                  <issue>12</issue>
                  <fpage>2641</fpage>
                  <lpage>2650</lpage>
                  <pub-id pub-id-type="doi">10.1681/ASN.2009070737</pub-id>
                  <!--<pub-id pub-id-type="pmcid">2794224</pub-id>-->
                  <?supplied-pmid 19926893?>
                  <pub-id pub-id-type="pmid">19926893</pub-id>
                </element-citation>
              </ref>
              <ref id="B58">
                <label>58</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lee</surname>
                      <given-names>SW</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes</article-title>
                  <source>Diabetes Res Clin Pract</source>
                  <year>2005</year>
                  <volume>69</volume>
                  <issue>2</issue>
                  <fpage>175</fpage>
                  <lpage>179</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.diabres.2004.12.010</pub-id>
                  <?supplied-pmid 16005367?>
                  <pub-id pub-id-type="pmid">16005367</pub-id>
                </element-citation>
              </ref>
              <ref id="B59">
                <label>59</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kitada</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Rodent models of diabetic nephropathy: their utility and limitations</article-title>
                  <source>Int J Nephrol Renovasc Dis</source>
                  <year>2016</year>
                  <volume>9</volume>
                  <fpage>279</fpage>
                  <lpage>290</lpage>
                  <pub-id pub-id-type="doi">10.2147/IJNRD.S103784</pub-id>
                  <!--<pub-id pub-id-type="pmcid">5115690</pub-id>-->
                  <?supplied-pmid 27881924?>
                  <pub-id pub-id-type="pmid">27881924</pub-id>
                </element-citation>
              </ref>
              <ref id="B60">
                <label>60</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kodera</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes</article-title>
                  <source>Biochem Biophys Res Commun</source>
                  <year>2014</year>
                  <volume>443</volume>
                  <issue>3</issue>
                  <fpage>828</fpage>
                  <lpage>833</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.bbrc.2013.12.049</pub-id>
                  <?supplied-pmid 24342619?>
                  <pub-id pub-id-type="pmid">24342619</pub-id>
                </element-citation>
              </ref>
              <ref id="B61">
                <label>61</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Palm</surname>
                      <given-names>F</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Differentiating between effects of streptozotocin per se and subsequent hyperglycemia on renal function and metabolism in the streptozotocin-diabetic rat model</article-title>
                  <source>Diabetes Metab Res Rev</source>
                  <year>2004</year>
                  <volume>20</volume>
                  <issue>6</issue>
                  <fpage>452</fpage>
                  <lpage>459</lpage>
                  <pub-id pub-id-type="doi">10.1002/dmrr.472</pub-id>
                  <?supplied-pmid 15386825?>
                  <pub-id pub-id-type="pmid">15386825</pub-id>
                </element-citation>
              </ref>
              <ref id="B62">
                <label>62</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kang</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Deng</surname>
                      <given-names>X</given-names>
                    </name>
                  </person-group>
                  <article-title>The endothelial glycocalyx: visualization and measurement</article-title>
                  <source>J Biomed</source>
                  <year>2017</year>
                  <volume>2</volume>
                  <fpage>120</fpage>
                  <lpage>123</lpage>
                  <pub-id pub-id-type="doi">10.7150/jbm.20986</pub-id>
                </element-citation>
              </ref>
              <ref id="B63">
                <label>63</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Savery</surname>
                      <given-names>MD</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The endothelial glycocalyx in syndecan-1 deficient mice</article-title>
                  <source>Microvasc Res</source>
                  <year>2013</year>
                  <volume>87</volume>
                  <fpage>83</fpage>
                  <lpage>91</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.mvr.2013.02.001</pub-id>
                  <!--<pub-id pub-id-type="pmcid">3627742</pub-id>-->
                  <?supplied-pmid 23428342?>
                  <pub-id pub-id-type="pmid">23428342</pub-id>
                </element-citation>
              </ref>
              <ref id="B64">
                <label>64</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Van den Berg</surname>
                      <given-names>BM</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The endothelial glycocalyx protects against myocardial edema</article-title>
                  <source>Circ Res</source>
                  <year>2003</year>
                  <volume>92</volume>
                  <issue>6</issue>
                  <fpage>592</fpage>
                  <lpage>594</lpage>
                  <pub-id pub-id-type="doi">10.1161/01.RES.0000065917.53950.75</pub-id>
                  <?supplied-pmid 12637366?>
                  <pub-id pub-id-type="pmid">12637366</pub-id>
                </element-citation>
              </ref>
              <ref id="B65">
                <label>65</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chappell</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The glycocalyx of the human umbilical vein endothelial cell: an impressive structure ex vivo but not in culture</article-title>
                  <source>Circ Res</source>
                  <year>2009</year>
                  <volume>104</volume>
                  <issue>11</issue>
                  <fpage>1313</fpage>
                  <lpage>1317</lpage>
                  <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.187831</pub-id>
                  <?supplied-pmid 19423849?>
                  <pub-id pub-id-type="pmid">19423849</pub-id>
                </element-citation>
              </ref>
              <ref id="B66">
                <label>66</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Haddad</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Experimental glomerular endothelial injury in vivo</article-title>
                  <source>PLoS One</source>
                  <year>2013</year>
                  <volume>8</volume>
                  <issue>10</issue>
                  <elocation-id>e78244</elocation-id>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0078244</pub-id>
                  <!--<pub-id pub-id-type="pmcid">3797051</pub-id>-->
                  <?supplied-pmid 24143262?>
                  <pub-id pub-id-type="pmid">24143262</pub-id>
                </element-citation>
              </ref>
              <ref id="B67">
                <label>67</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Warner</surname>
                      <given-names>RL</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Marasmius oreades lectin induces renal thrombotic microangiopathic lesions</article-title>
                  <source>Exp Mol Pathol</source>
                  <year>2004</year>
                  <volume>77</volume>
                  <issue>2</issue>
                  <fpage>77</fpage>
                  <lpage>84</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.yexmp.2004.04.003</pub-id>
                  <?supplied-pmid 15351229?>
                  <pub-id pub-id-type="pmid">15351229</pub-id>
                </element-citation>
              </ref>
              <ref id="B68">
                <label>68</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Reitsma</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Endothelial glycocalyx structure in the intact carotid artery: a two-photon laser scanning microscopy study</article-title>
                  <source>J Vasc Res</source>
                  <year>2011</year>
                  <volume>48</volume>
                  <issue>4</issue>
                  <fpage>297</fpage>
                  <lpage>306</lpage>
                  <pub-id pub-id-type="doi">10.1159/000322176</pub-id>
                  <?supplied-pmid 21273784?>
                  <pub-id pub-id-type="pmid">21273784</pub-id>
                </element-citation>
              </ref>
              <ref id="B69">
                <label>69</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Padberg</surname>
                      <given-names>J-S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Damage of the endothelial glycocalyx in chronic kidney disease</article-title>
                  <source>Atherosclerosis</source>
                  <year>2014</year>
                  <volume>234</volume>
                  <issue>2</issue>
                  <fpage>335</fpage>
                  <lpage>343</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2014.03.016</pub-id>
                  <?supplied-pmid 24727235?>
                  <pub-id pub-id-type="pmid">24727235</pub-id>
                </element-citation>
              </ref>
              <ref id="B70">
                <label>70</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wiesinger</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Nanomechanics of the endothelial glycocalyx in experimental sepsis</article-title>
                  <source>PLoS One</source>
                  <year>2013</year>
                  <volume>8</volume>
                  <issue>11</issue>
                  <elocation-id>e80905</elocation-id>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0080905</pub-id>
                  <!--<pub-id pub-id-type="pmcid">3835794</pub-id>-->
                  <?supplied-pmid 24278345?>
                  <pub-id pub-id-type="pmid">24278345</pub-id>
                </element-citation>
              </ref>
              <ref id="B71">
                <label>71</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Targosz-Korecka</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>AFM-based detection of glycocalyx degradation and endothelial stiffening in the db/db mouse model of diabetes</article-title>
                  <source>Sci Rep</source>
                  <year>2017</year>
                  <volume>7</volume>
                  <issue>1</issue>
                  <elocation-id>15951</elocation-id>
                  <pub-id pub-id-type="doi">10.1038/s41598-017-16179-7</pub-id>
                  <!--<pub-id pub-id-type="pmcid">5698475</pub-id>-->
                  <?supplied-pmid 29162916?>
                  <pub-id pub-id-type="pmid">29162916</pub-id>
                </element-citation>
              </ref>
              <ref id="B72">
                <label>72</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Marsh</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Waugh</surname>
                      <given-names>RE</given-names>
                    </name>
                  </person-group>
                  <article-title>Quantifying the mechanical properties of the endothelial glycocalyx with atomic force microscopy</article-title>
                  <source>J Vis Exp</source>
                  <year>2013</year>
                  <issue>72</issue>
                  <elocation-id>50163</elocation-id>
                  <!--<pub-id pub-id-type="pmcid">3605807</pub-id>-->
                  <?supplied-pmid 23462566?>
                  <pub-id pub-id-type="pmid">23462566</pub-id>
                </element-citation>
              </ref>
              <ref id="B73">
                <label>73</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Henry</surname>
                      <given-names>CBS</given-names>
                    </name>
                    <name>
                      <surname>Duling</surname>
                      <given-names>BR</given-names>
                    </name>
                  </person-group>
                  <article-title>TNF-alpha increases entry of macromolecules into luminal endothelial cell glycocalyx</article-title>
                  <source>Am J Physiol Heart Circ Physiol</source>
                  <year>2000</year>
                  <volume>279</volume>
                  <issue>6</issue>
                  <fpage>H2815</fpage>
                  <lpage>H2823</lpage>
                  <pub-id pub-id-type="doi">10.1152/ajpheart.2000.279.6.H2815</pub-id>
                  <?supplied-pmid 11087236?>
                  <pub-id pub-id-type="pmid">11087236</pub-id>
                </element-citation>
              </ref>
              <ref id="B74">
                <label>74</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lipowsky</surname>
                      <given-names>HH</given-names>
                    </name>
                    <name>
                      <surname>Lescanic</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Shear dependent adhesion of leukocytes and lectins to the endothelium and concurrent changes in thickness of the glycocalyx of post-capillary venules in the low flow state</article-title>
                  <source>Microcirculation</source>
                  <year>2013</year>
                  <volume>20</volume>
                  <issue>2</issue>
                  <fpage>149</fpage>
                  <lpage>157</lpage>
                  <pub-id pub-id-type="doi">10.1111/micc.12013</pub-id>
                  <!--<pub-id pub-id-type="pmcid">3541453</pub-id>-->
                  <?supplied-pmid 22963321?>
                  <pub-id pub-id-type="pmid">22963321</pub-id>
                </element-citation>
              </ref>
              <ref id="B75">
                <label>75</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gao</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Lipowsky</surname>
                      <given-names>HH</given-names>
                    </name>
                  </person-group>
                  <article-title>Composition of the endothelial glycocalyx and its relation to its thickness and diffusion of small solutes</article-title>
                  <source>Microvasc Res</source>
                  <year>2010</year>
                  <volume>80</volume>
                  <issue>3</issue>
                  <fpage>394</fpage>
                  <lpage>401</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.mvr.2010.06.005</pub-id>
                  <!--<pub-id pub-id-type="pmcid">2962421</pub-id>-->
                  <?supplied-pmid 20600162?>
                  <pub-id pub-id-type="pmid">20600162</pub-id>
                </element-citation>
              </ref>
              <ref id="B76">
                <label>76</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ebong</surname>
                      <given-names>EE</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Imaging the endothelial glycocalyx in vitro by rapid freezing/freeze substitution transmission electron microscopy</article-title>
                  <source>Arterioscler Thromb Vasc Biol</source>
                  <year>2011</year>
                  <volume>31</volume>
                  <issue>8</issue>
                  <fpage>1908</fpage>
                  <lpage>1915</lpage>
                  <pub-id pub-id-type="doi">10.1161/ATVBAHA.111.225268</pub-id>
                  <!--<pub-id pub-id-type="pmcid">3141106</pub-id>-->
                  <?supplied-pmid 21474821?>
                  <pub-id pub-id-type="pmid">21474821</pub-id>
                </element-citation>
              </ref>
              <ref id="B77">
                <label>77</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dogné</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Endothelial glycocalyx as a shield against diabetic vascular complications: involvement of hyaluronan and hyaluronidases</article-title>
                  <source>Arterioscler Thromb Vasc Biol</source>
                  <year>2018</year>
                  <volume>38</volume>
                  <issue>7</issue>
                  <fpage>1427</fpage>
                  <lpage>1439</lpage>
                  <pub-id pub-id-type="doi">10.1161/ATVBAHA.118.310839</pub-id>
                  <!--<pub-id pub-id-type="pmcid">6039403</pub-id>-->
                  <?supplied-pmid 29880486?>
                  <pub-id pub-id-type="pmid">29880486</pub-id>
                </element-citation>
              </ref>
              <ref id="B78">
                <label>78</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Onions</surname>
                      <given-names>KL</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>VEGFC reduces glomerular albumin permeability and protects against alterations in VEGF receptor expression in diabetic nephropathy</article-title>
                  <source>Diabetes</source>
                  <year>2019</year>
                  <volume>68</volume>
                  <issue>1</issue>
                  <fpage>172</fpage>
                  <lpage>187</lpage>
                  <pub-id pub-id-type="doi">10.2337/db18-0045</pub-id>
                  <?supplied-pmid 30389746?>
                  <pub-id pub-id-type="pmid">30389746</pub-id>
                </element-citation>
              </ref>
              <ref id="B79">
                <label>79</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wolf</surname>
                      <given-names>RA</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The serum kinetics of bovine testicular hyaluronidase in dogs, rats and humans</article-title>
                  <source>J Pharmacol Exp Ther</source>
                  <year>1982</year>
                  <volume>222</volume>
                  <issue>2</issue>
                  <fpage>331</fpage>
                  <lpage>337</lpage>
                  <?supplied-pmid 7097553?>
                  <pub-id pub-id-type="pmid">7097553</pub-id>
                </element-citation>
              </ref>
              <ref id="B80">
                <label>80</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dane</surname>
                      <given-names>MJC</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Glomerular endothelial surface layer acts as a barrier against albumin filtration</article-title>
                  <source>Am J Pathol</source>
                  <year>2013</year>
                  <volume>182</volume>
                  <issue>5</issue>
                  <fpage>1532</fpage>
                  <lpage>1540</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ajpath.2013.01.049</pub-id>
                  <?supplied-pmid 23518410?>
                  <pub-id pub-id-type="pmid">23518410</pub-id>
                </element-citation>
              </ref>
              <ref id="B81">
                <label>81</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nagai</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts</article-title>
                  <source>Hypertension</source>
                  <year>2005</year>
                  <volume>46</volume>
                  <issue>4</issue>
                  <fpage>1039</fpage>
                  <lpage>1045</lpage>
                  <pub-id pub-id-type="doi">10.1161/01.HYP.0000174593.88899.68</pub-id>
                  <?supplied-pmid 16087786?>
                  <pub-id pub-id-type="pmid">16087786</pub-id>
                </element-citation>
              </ref>
              <ref id="B82">
                <label>82</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nishiyama</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability</article-title>
                  <source>Hypertension</source>
                  <year>2005</year>
                  <volume>45</volume>
                  <issue>4</issue>
                  <fpage>710</fpage>
                  <lpage>716</lpage>
                  <pub-id pub-id-type="doi">10.1161/01.HYP.0000154681.38944.9a</pub-id>
                  <?supplied-pmid 15699469?>
                  <pub-id pub-id-type="pmid">15699469</pub-id>
                </element-citation>
              </ref>
              <ref id="B83">
                <label>83</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shibata</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease</article-title>
                  <source>Nat Med</source>
                  <year>2008</year>
                  <volume>14</volume>
                  <issue>12</issue>
                  <fpage>1370</fpage>
                  <lpage>1376</lpage>
                  <pub-id pub-id-type="doi">10.1038/nm.1879</pub-id>
                  <?supplied-pmid 19029984?>
                  <pub-id pub-id-type="pmid">19029984</pub-id>
                </element-citation>
              </ref>
              <ref id="B84">
                <label>84</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nguyen Dinh Cat</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure</article-title>
                  <source>FASEB J</source>
                  <year>2010</year>
                  <volume>24</volume>
                  <issue>7</issue>
                  <fpage>2454</fpage>
                  <lpage>2463</lpage>
                  <pub-id pub-id-type="doi">10.1096/fj.09-147926</pub-id>
                  <?supplied-pmid 20299606?>
                  <pub-id pub-id-type="pmid">20299606</pub-id>
                </element-citation>
              </ref>
              <ref id="B85">
                <label>85</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Meneton</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule</article-title>
                  <source>Am J Physiol Renal Physiol</source>
                  <year>2004</year>
                  <volume>287</volume>
                  <issue>4</issue>
                  <fpage>F593</fpage>
                  <lpage>F601</lpage>
                  <pub-id pub-id-type="doi">10.1152/ajprenal.00454.2003</pub-id>
                  <?supplied-pmid 15345493?>
                  <pub-id pub-id-type="pmid">15345493</pub-id>
                </element-citation>
              </ref>
              <ref id="B86">
                <label>86</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Farman</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Rafestin-Oblin</surname>
                      <given-names>ME</given-names>
                    </name>
                  </person-group>
                  <article-title>Multiple aspects of mineralocorticoid selectivity</article-title>
                  <source>Am J Physiol Renal Physiol</source>
                  <year>2001</year>
                  <volume>280</volume>
                  <issue>2</issue>
                  <fpage>F181</fpage>
                  <lpage>F192</lpage>
                  <pub-id pub-id-type="doi">10.1152/ajprenal.2001.280.2.F181</pub-id>
                  <?supplied-pmid 11208593?>
                  <pub-id pub-id-type="pmid">11208593</pub-id>
                </element-citation>
              </ref>
              <ref id="B87">
                <label>87</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gilet</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Aldosterone up-regulates MMP-9 and MMP-9/NGAL expression in human neutrophils through p38, ERK1/2 and PI3K pathways</article-title>
                  <source>Exp Cell Res</source>
                  <year>2015</year>
                  <volume>331</volume>
                  <issue>1</issue>
                  <fpage>152</fpage>
                  <lpage>163</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.yexcr.2014.11.004</pub-id>
                  <?supplied-pmid 25449697?>
                  <pub-id pub-id-type="pmid">25449697</pub-id>
                </element-citation>
              </ref>
              <ref id="B88">
                <label>88</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bienvenu</surname>
                      <given-names>LA</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis</article-title>
                  <source>Endocrinology</source>
                  <year>2012</year>
                  <volume>153</volume>
                  <issue>7</issue>
                  <fpage>3416</fpage>
                  <lpage>3425</lpage>
                  <pub-id pub-id-type="doi">10.1210/en.2011-2098</pub-id>
                  <?supplied-pmid 22653557?>
                  <pub-id pub-id-type="pmid">22653557</pub-id>
                </element-citation>
              </ref>
              <ref id="B89">
                <label>89</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rickard</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure</article-title>
                  <source>Hypertension</source>
                  <year>2009</year>
                  <volume>54</volume>
                  <issue>3</issue>
                  <fpage>537</fpage>
                  <lpage>543</lpage>
                  <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.109.131110</pub-id>
                  <?supplied-pmid 19635989?>
                  <pub-id pub-id-type="pmid">19635989</pub-id>
                </element-citation>
              </ref>
              <ref id="B90">
                <label>90</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bergmann</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Aldosterone abrogates nuclear factor kappaB-mediated tumor necrosis factor alpha production in human neutrophils via the mineralocorticoid receptor</article-title>
                  <source>Hypertension</source>
                  <year>2010</year>
                  <volume>55</volume>
                  <issue>2</issue>
                  <fpage>370</fpage>
                  <lpage>379</lpage>
                  <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.109.141309</pub-id>
                  <?supplied-pmid 20065153?>
                  <pub-id pub-id-type="pmid">20065153</pub-id>
                </element-citation>
              </ref>
              <ref id="B91">
                <label>91</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Drake-Holland</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Noble</surname>
                      <given-names>MI</given-names>
                    </name>
                  </person-group>
                  <article-title>The important new drug target in cardiovascular medicine--the vascular glycocalyx</article-title>
                  <source>Cardiovasc Hematol Disord Drug Targets</source>
                  <year>2009</year>
                  <volume>9</volume>
                  <issue>2</issue>
                  <fpage>118</fpage>
                  <lpage>123</lpage>
                  <pub-id pub-id-type="doi">10.2174/187152909788488708</pub-id>
                  <pub-id pub-id-type="pmid">19519370</pub-id>
                </element-citation>
              </ref>
              <ref id="B92">
                <label>92</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Broekhuizen</surname>
                      <given-names>LN</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease</article-title>
                  <source>Curr Opin Lipidol</source>
                  <year>2009</year>
                  <volume>20</volume>
                  <issue>1</issue>
                  <fpage>57</fpage>
                  <lpage>62</lpage>
                  <pub-id pub-id-type="doi">10.1097/MOL.0b013e328321b587</pub-id>
                  <?supplied-pmid 19106708?>
                  <pub-id pub-id-type="pmid">19106708</pub-id>
                </element-citation>
              </ref>
              <ref id="B93">
                <label>93</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Becker</surname>
                      <given-names>BF</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Therapeutic strategies targeting the endothelial glycocalyx: acute deficits, but great potential</article-title>
                  <source>Cardiovasc Res</source>
                  <year>2010</year>
                  <volume>87</volume>
                  <issue>2</issue>
                  <fpage>300</fpage>
                  <lpage>310</lpage>
                  <pub-id pub-id-type="doi">10.1093/cvr/cvq137</pub-id>
                  <?supplied-pmid 20462866?>
                  <pub-id pub-id-type="pmid">20462866</pub-id>
                </element-citation>
              </ref>
              <ref id="B94">
                <label>94</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Derosa</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus</article-title>
                  <source>Diabetes Res Clin Pract</source>
                  <year>2005</year>
                  <volume>70</volume>
                  <issue>2</issue>
                  <fpage>119</fpage>
                  <lpage>125</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.diabres.2005.03.020</pub-id>
                  <?supplied-pmid 16188574?>
                  <pub-id pub-id-type="pmid">16188574</pub-id>
                </element-citation>
              </ref>
              <ref id="B95">
                <label>95</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Maxwell</surname>
                      <given-names>PR</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes</article-title>
                  <source>Diabet Med</source>
                  <year>2001</year>
                  <volume>18</volume>
                  <issue>10</issue>
                  <fpage>777</fpage>
                  <lpage>780</lpage>
                  <pub-id pub-id-type="doi">10.1046/j.1464-5491.2001.00542.x</pub-id>
                  <?supplied-pmid 11678966?>
                  <pub-id pub-id-type="pmid">11678966</pub-id>
                </element-citation>
              </ref>
              <ref id="B96">
                <label>96</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McKittrick</surname>
                      <given-names>IB</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Urinary matrix metalloproteinase activities: biomarkers for plaque angiogenesis and nephropathy in diabetes</article-title>
                  <source>Am J Physiol Renal Physiol</source>
                  <year>2011</year>
                  <volume>301</volume>
                  <issue>6</issue>
                  <fpage>F1326</fpage>
                  <lpage>F1333</lpage>
                  <pub-id pub-id-type="doi">10.1152/ajprenal.00267.2011</pub-id>
                  <!--<pub-id pub-id-type="pmcid">3233865</pub-id>-->
                  <?supplied-pmid 21921021?>
                  <pub-id pub-id-type="pmid">21921021</pub-id>
                </element-citation>
              </ref>
              <ref id="B97">
                <label>97</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Diamant</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Elevated matrix metalloproteinase-2 and -9 in urine, but not in serum, are markers of type 1 diabetic nephropathy</article-title>
                  <source>Diabet Med</source>
                  <year>2001</year>
                  <volume>18</volume>
                  <issue>5</issue>
                  <fpage>423</fpage>
                  <lpage>424</lpage>
                  <?supplied-pmid 11472458?>
                  <pub-id pub-id-type="pmid">11472458</pub-id>
                </element-citation>
              </ref>
              <ref id="B98">
                <label>98</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Van der Zijl</surname>
                      <given-names>NJ</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Urinary matrix metalloproteinase-8 and -9 activities in type 2 diabetic subjects: a marker of incipient diabetic nephropathy?</article-title>
                  <source>Clin Biochem</source>
                  <year>2010</year>
                  <volume>43</volume>
                  <issue>7–8</issue>
                  <fpage>635</fpage>
                  <lpage>639</lpage>
                  <?supplied-pmid 20184870?>
                  <pub-id pub-id-type="pmid">20184870</pub-id>
                </element-citation>
              </ref>
              <ref id="B99">
                <label>99</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ferreira</surname>
                      <given-names>JP</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Proteomic and mechanistic analysis of spironolactone in patients at risk for HF</article-title>
                  <source>JACC Heart Fail</source>
                  <year>2021</year>
                  <volume>9</volume>
                  <issue>4</issue>
                  <fpage>268</fpage>
                  <lpage>277</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jchf.2020.11.010</pub-id>
                  <?supplied-pmid 33549556?>
                  <pub-id pub-id-type="pmid">33549556</pub-id>
                </element-citation>
              </ref>
              <ref id="B100">
                <label>100</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ferreira</surname>
                      <given-names>JP</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Influence of spironolactone on matrix metalloproteinase-2 in acute decompensated heart failure</article-title>
                  <source>Arq Bras Cardiol</source>
                  <year>2015</year>
                  <volume>104</volume>
                  <issue>4</issue>
                  <fpage>308</fpage>
                  <lpage>314</lpage>
                  <!--<pub-id pub-id-type="pmcid">4415867</pub-id>-->
                  <?supplied-pmid 25993594?>
                  <pub-id pub-id-type="pmid">25993594</pub-id>
                </element-citation>
              </ref>
              <ref id="B101">
                <label>101</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Li</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology</article-title>
                  <source>Can J Cardiol</source>
                  <year>2009</year>
                  <volume>25</volume>
                  <issue>9</issue>
                  <fpage>523</fpage>
                  <lpage>526</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0828-282X(09)70138-2</pub-id>
                  <!--<pub-id pub-id-type="pmcid">2780895</pub-id>-->
                  <?supplied-pmid 19746242?>
                  <pub-id pub-id-type="pmid">19746242</pub-id>
                </element-citation>
              </ref>
              <ref id="B102">
                <label>102</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mayyas</surname>
                      <given-names>F</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The role of spironolactone on myocardial oxidative stress in rat model of streptozotocin-induced diabetes</article-title>
                  <source>Cardiovasc Ther</source>
                  <year>2017</year>
                  <volume>35</volume>
                  <issue>2</issue>
                  <elocation-id>e12242</elocation-id>
                  <pub-id pub-id-type="doi">10.1111/1755-5922.12242</pub-id>
                  <?supplied-pmid 27992114?>
                  <pub-id pub-id-type="pmid">27992114</pub-id>
                </element-citation>
              </ref>
              <ref id="B103">
                <label>103</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Banki</surname>
                      <given-names>NF</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Aldosterone antagonists in monotherapy are protective against streptozotocin-induced diabetic nephropathy in rats</article-title>
                  <source>PLoS One</source>
                  <year>2012</year>
                  <volume>7</volume>
                  <issue>6</issue>
                  <elocation-id>e39938</elocation-id>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0039938</pub-id>
                  <!--<pub-id pub-id-type="pmcid">3386228</pub-id>-->
                  <?supplied-pmid 22761931?>
                  <pub-id pub-id-type="pmid">22761931</pub-id>
                </element-citation>
              </ref>
              <ref id="B104">
                <label>104</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fujisawa</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats</article-title>
                  <source>Kidney Int</source>
                  <year>2004</year>
                  <volume>66</volume>
                  <issue>4</issue>
                  <fpage>1493</fpage>
                  <lpage>1502</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00913.x</pub-id>
                  <?supplied-pmid 15458443?>
                  <pub-id pub-id-type="pmid">15458443</pub-id>
                </element-citation>
              </ref>
              <ref id="B105">
                <label>105</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Toyonaga</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production</article-title>
                  <source>Nephrol Dial Transplant</source>
                  <year>2011</year>
                  <volume>26</volume>
                  <issue>8</issue>
                  <fpage>2475</fpage>
                  <lpage>2484</lpage>
                  <pub-id pub-id-type="doi">10.1093/ndt/gfq750</pub-id>
                  <?supplied-pmid 21220752?>
                  <pub-id pub-id-type="pmid">21220752</pub-id>
                </element-citation>
              </ref>
              <ref id="B106">
                <label>106</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Satchell</surname>
                      <given-names>SC</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF</article-title>
                  <source>Kidney Int</source>
                  <year>2006</year>
                  <volume>69</volume>
                  <issue>9</issue>
                  <fpage>1633</fpage>
                  <lpage>1640</lpage>
                  <pub-id pub-id-type="doi">10.1038/sj.ki.5000277</pub-id>
                  <?supplied-pmid 16557232?>
                  <pub-id pub-id-type="pmid">16557232</pub-id>
                </element-citation>
              </ref>
              <ref id="B107">
                <label>107</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gregory</surname>
                      <given-names>MC</given-names>
                    </name>
                  </person-group>
                  <article-title>The clinical features of thin basement membrane nephropathy</article-title>
                  <source>Semin Nephrol</source>
                  <year>2005</year>
                  <volume>25</volume>
                  <issue>3</issue>
                  <fpage>140</fpage>
                  <lpage>145</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.semnephrol.2005.01.004</pub-id>
                  <pub-id pub-id-type="pmid">15880323</pub-id>
                </element-citation>
              </ref>
              <ref id="B108">
                <label>108</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Savige</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Thin basement membrane nephropathy</article-title>
                  <source>Kidney Int</source>
                  <year>2003</year>
                  <volume>64</volume>
                  <issue>4</issue>
                  <fpage>1169</fpage>
                  <lpage>1178</lpage>
                  <pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00234.x</pub-id>
                  <pub-id pub-id-type="pmid">12969134</pub-id>
                </element-citation>
              </ref>
            </ref-list>
            <notes notes-type="version-changes">
              <sec sec-type="version-changes">
                <label>Version 1</label>
                <title>02/07/2023</title>
                <p>In-Press Preview</p>
              </sec>
              <sec sec-type="version-changes">
                <label>Version 2</label>
                <title>03/08/2023</title>
                <p>Electronic publication</p>
              </sec>
            </notes>
          </back>
          <floats-group>
            <fig position="float" id="F1">
              <label>Figure 1</label>
              <caption>
                <title>Development of albuminuria and increased glomerular permeability in early diabetic nephropathy is ameliorated by MR antagonism.</title>
                <p>(<bold>A</bold>) Schematic overview of STZ-induced diabetic model and spironolactone (spiro) treatment protocol for male Wistar rats. An injection of STZ was given at week 0. Four weeks after STZ injection, spiro (an MR inhibitor) was given for 28 days, and rats were culled at week 8 after STZ injection. Rats were randomized to receive STZ and spiro. (<bold>B</bold>) Treatment with spiro for 28 days reduced the fold change in urinary albumin/creatinine ratio (uACR) from initiation of treatment, week 4 to week 8 (control, <italic toggle="yes">n</italic> = 10; diabetes, <italic toggle="yes">n</italic> = 12; diabetes-spiro, <italic toggle="yes">n</italic> = 13). Data were log transformed and presented as log<sub>2</sub> (fold change). (<bold>C</bold>) Representative images of an isolated glomerulus stained with R18 and Alexa Fluor 488–BSA (AF488-BSA). Magnification, 20<italic toggle="yes"><bold>×</bold></italic>. (<bold>D</bold>) Glomerular albumin permeability (P<italic toggle="yes">s’<sub>alb</sub></italic>) was measured at week 8 (control, <italic toggle="yes">n</italic> = 7 rats [32 glomeruli]; diabetes, <italic toggle="yes">n</italic> = 8 [36 glomeruli]; diabetes-spiro, <italic toggle="yes">n</italic> = 5 [21 glomeruli]). In <bold>B</bold> and <bold>D</bold>, 1-way ANOVA was used for statistical analysis, followed by Tukey’s multiple comparisons. Each dot, triangle, and square on the graph represents a rat. Data are expressed as mean ± SEM. **<italic toggle="yes">P</italic> &lt; 0.01; ***<italic toggle="yes">P</italic> &lt; 0.001.</p>
              </caption>
              <graphic xlink:href="jciinsight-8-154164-g189" position="float"/>
            </fig>
            <fig position="float" id="F2">
              <label>Figure 2</label>
              <caption>
                <title>Fluorescence profile peak-to-peak measurements confirm that glomerular endothelial glycocalyx damage is prevented by MR antagonism and correlates strongly with glomerular albumin permeability.</title>
                <p>Rats were perfused with Ringer solution, and the left kidney was removed for lectin staining. (<bold>A</bold>) Representative images show glomerular capillaries labeled red (R18) and the luminal glomerular endothelial glycocalyx (GEnGlx) labeled green with <italic toggle="yes">Marasmium oreades</italic> agglutinin (MOA) or wheat germ agglutinin (WGA). Scale bars: 20 μm and 5 μm. ROI, region of interest for fluorescence profile peak-to-peak (P-P)measurement. (<bold>B</bold>) Representative relative intensity peaks of R18 (red) and MOA (green) profiles showing P-P assessment of the GEnGlx; Gaussian curves (dashed lines) were fit to the raw intensity data of each plot for P-P measurements. (<bold>C</bold> and <bold>D</bold>) Quantification at week 8 after STZ of GEnGlx MOA labeling P-P (control, <italic toggle="yes">n</italic> = 7; diabetes, <italic toggle="yes">n</italic> = 6; diabetes-spironolactone [diabetes-spiro], <italic toggle="yes">n</italic> = 7) and functional association with the rate of glomerular albumin leakage (P<italic toggle="yes">s’<sub>alb</sub></italic>) (<italic toggle="yes">n</italic> = 9). (<bold>E</bold> and <bold>F</bold>) Quantification at week 8 after STZ of GEnGlx WGA labeling P-P (control, <italic toggle="yes">n</italic> = 5; diabetes, <italic toggle="yes">n</italic> = 6; diabetes-spiro, <italic toggle="yes">n</italic> = 5) and functional association with the rate of glomerular P<italic toggle="yes">s’<sub>alb</sub></italic> (<italic toggle="yes">n</italic> = 16). In <bold>C</bold> and <bold>E</bold>, 1-way ANOVA was used for statistical analysis, followed by Tukey’s multiple comparisons. Each dot, triangle, and square on the graph represents a rat. Data are expressed as mean ± SEM. **<italic toggle="yes">P</italic> &lt; 0.01; ***<italic toggle="yes">P</italic> &lt; 0.001.</p>
              </caption>
              <graphic xlink:href="jciinsight-8-154164-g190" position="float"/>
            </fig>
            <fig position="float" id="F3">
              <label>Figure 3</label>
              <caption>
                <title>The effect of MR antagonism in preventing the diabetes-induced increase in glomerular permeability is dependent on the glomerular endothelial glycocalyx.</title>
                <p>(<bold>A</bold>) Schematic overview of enzymatic degradation of the glomerular endothelial glycocalyx (GEnGlx) with hyaluronidase on spironolactone-treated (spiro-treated) male Wistar rats. An injection of STZ was given at week 0. Four weeks after STZ injection, spiro (an MR inhibitor) was given for 28 days, and rats were given hyaluronidase (200 units) at week 8 after STZ via tail vein injection 1 hour before being culled for tissue collection. Rats were randomized to receive hyaluronidase. (<bold>B</bold> and <bold>C</bold>) Quantification at week 8 after STZ of GEnGlx WGA labeling peak-to-peak (diabetes-spiro, <italic toggle="yes">n</italic> = 5; diabetes-spiro-enzyme, <italic toggle="yes">n</italic> = 5) and GEnGlx MOA labeling peak-to-peak (diabetes-spiro, <italic toggle="yes">n</italic> = 5; diabetes-spiro-enzyme, <italic toggle="yes">n</italic> = 5) confirmed enzyme degradation of GEnGlx. In <bold>B</bold> and <bold>C</bold>, unpaired <italic toggle="yes">t</italic> test was used for statistical analysis. (<bold>D</bold>) Albuminuria levels returned to those expected in vehicle treated diabetic rats. Urinary albumin/creatinine ratio (uACR) was determined from the same rats (<italic toggle="yes">n</italic> = 5) at week 4 after STZ (diabetes before spiro 4wk), week 8 after treatment with spiro (diabetes-spiro 8wk preenzyme), and week 8 after hyaluronidase (diabetes-spiro 8wk post-enzyme). The connecting line (gray) represents the same rat for each data point. Repeated-measures 1-way ANOVA was used for statistical analysis, followed by Tukey’s multiple comparisons. Each triangle or square on the graph represents a rat. Data are expressed as mean ± SEM. *<italic toggle="yes">P</italic> &lt; 0.05; ***<italic toggle="yes">P</italic> &lt; 0.001.</p>
              </caption>
              <graphic xlink:href="jciinsight-8-154164-g191" position="float"/>
            </fig>
            <fig position="float" id="F4">
              <label>Figure 4</label>
              <caption>
                <title>Increased matrix metalloproteinase activity in early diabetic nephropathy is ameliorated by MR antagonism.</title>
                <p>(<bold>A</bold> and <bold>D</bold>) Matrix metalloproteinase (MMP) activities were measured for the sheddases MMP2 and MMP9. Systemic circulation of plasma active MMP2 (<bold>A</bold>) and plasma active MMP9 (<bold>D</bold>) (control, <italic toggle="yes">n</italic> = 10; diabetes, <italic toggle="yes">n</italic> = 7; diabetes-spironolactone [diabetes-spiro], <italic toggle="yes">n</italic> = 13) were determined. (<bold>B</bold> and <bold>E</bold>) Localized activity of glomerular active MMP2 (<bold>B</bold>) and glomerular active MMP9 (<bold>E</bold>) (control, <italic toggle="yes">n</italic> = 8; diabetes, <italic toggle="yes">n</italic> = 7; diabetes-spiro, <italic toggle="yes">n</italic> = 8) were determined from isolated glomeruli and normalized to glomerular total protein. (<bold>C</bold> and <bold>F</bold>) Urine active MMP2 (<bold>C</bold>) and urine active MMP9 (<bold>F</bold>) (control, <italic toggle="yes">n</italic> = 13; diabetes, <italic toggle="yes">n</italic> =11; diabetes-spiro, <italic toggle="yes">n</italic> = 15) were determined and normalized to urine creatinine. Each dot, triangle, and square represents a rat. The fold change relative to control was calculated to enable pooling of results from different experiments. One-way ANOVA was used for statistical analysis, followed by Tukey’s multiple comparisons. Data are expressed as mean ± SEM. *<italic toggle="yes">P</italic> &lt; 0.05; **<italic toggle="yes">P</italic> &lt; 0.01; ***<italic toggle="yes">P</italic> &lt; 0.001.</p>
              </caption>
              <graphic xlink:href="jciinsight-8-154164-g192" position="float"/>
            </fig>
            <fig position="float" id="F5">
              <label>Figure 5</label>
              <caption>
                <title>Exposing human GEnC to diabetic conditions resulted in MMP upregulation and GEnGlx damage, effects ameliorated by MR antagonism.</title>
                <p>Human conditionally immortalized glomerular endothelial cells (CiGEnC) were maintained in the presence of glucose, insulin, TNF-α, and IL-6 to mimic a diabetic environment. (<bold>A</bold>, <bold>C</bold>, <bold>E</bold>, and <bold>G</bold>) Representative images of CiGEnC stained with MMP2, MMP9, MMP14, or WGA lectin (an endothelial glycocalyx label) shown for control, diabetes, and diabetes-spironolactone (diabetes-spiro) samples. DAPI, nuclear label; R18, endothelial membrane label. Scale bars: 25 μm. (<bold>B</bold>, <bold>D</bold>, <bold>F</bold>, and <bold>H</bold>) Fluorescence intensity was quantified in CiGEnC for MMP2 (control, <italic toggle="yes">n</italic> = 35; diabetes, <italic toggle="yes">n</italic> = 34; diabetes-spiro, <italic toggle="yes">n</italic> = 33), MMP9 (control, <italic toggle="yes">n</italic> = 23; diabetes, <italic toggle="yes">n</italic> = 24; diabetes-spiro, <italic toggle="yes">n</italic> = 19), MMP14 (control, <italic toggle="yes">n</italic> = 18; diabetes, <italic toggle="yes">n</italic> = 31; diabetes-spiro, <italic toggle="yes">n</italic> = 14), and WGA lectin (control, <italic toggle="yes">n</italic> = 30; diabetes, <italic toggle="yes">n</italic> = 41; diabetes-spiro, <italic toggle="yes">n</italic> = 43). In <bold>A</bold> and <bold>B</bold>, 1-way ANOVA was used for statistical analysis, followed by Tukey’s multiple comparisons. In <bold>C</bold> and <bold>D</bold>, Kruskal-Wallis test was used for statistical analysis. Data are expressed as mean ± SEM. **<italic toggle="yes">P</italic> &lt; 0.01; ***<italic toggle="yes">P</italic> &lt; 0.001.</p>
              </caption>
              <graphic xlink:href="jciinsight-8-154164-g193" position="float"/>
            </fig>
            <fig position="float" id="F6">
              <label>Figure 6</label>
              <caption>
                <title>The glomerular endothelial glycocalyx is damaged in human diabetic nephropathy.</title>
                <p>(<bold>A</bold>) Representative images show glomerular capillaries labeled red (R18) and the luminal glomerular endothelial glycocalyx (GEnGlx) labeled green with <italic toggle="yes">Ulex europaeus</italic> agglutinin I (UEA-I) in renal biopsies from thin basement membrane nephropathy (TBMN) and diabetic nephropathy (DN) patients from Bristol, United Kingdom, and from histologically normal controls and patients with DN from Bari, Italy. Scale bar: 40 μm and 5 μm. (<bold>B</bold>) Quantification of GEnGlx UEA labeling peak-to-peak (Bristol: TBMN, <italic toggle="yes">n</italic> = 8; diabetes, <italic toggle="yes">n</italic> = 12; Bari: control, <italic toggle="yes">n</italic> = 7; diabetes, <italic toggle="yes">n</italic> = 7) confirms that GEnGlx damage may contribute to the disease phenotype seen in human DN. Unpaired <italic toggle="yes">t</italic> test was used for statistical analysis. (<bold>C</bold>) The number of samples, glomeruli, and capillaries used to analyze each group. Each dot or square on the graph represents a patient. Data are expressed as mean ± SEM. ***<italic toggle="yes">P</italic> &lt;0.001.</p>
              </caption>
              <graphic xlink:href="jciinsight-8-154164-g194" position="float"/>
            </fig>
            <fig position="float" id="F7">
              <label>Figure 7</label>
              <caption>
                <title>Matrix metalloproteinase activity in human diabetes is reduced by MR antagonism.</title>
                <p>Matrix metalloproteinase (MMP) activities were measured for the sheddases MMP2 and MMP9. (<bold>A</bold> and <bold>B</bold>) Urine active MMP2 and urine active MMP9 were determined and normalized to urine creatinine (placebo, <italic toggle="yes">n</italic> = 20; spironolactone, <italic toggle="yes">n</italic> = 15). Data were log transformed and presented as log<sub>2</sub> (fold change). Mean fold change in placebo and spironolactone groups were presented for urine active MMP2 and urine active MMP9. Normalized changes for each individual taking placebo/spironolactone are also displayed to illustrate the variability in individuals’ progression with time/response. Paired <italic toggle="yes">t</italic> test was used for statistical analysis between baseline and week-48 data. Data are expressed as mean ± SEM. *<italic toggle="yes">P</italic> &lt; 0.05; **<italic toggle="yes">P</italic> &lt; 0.01. Individual data for urine active MMP fold change from baseline to week 48 were presented for placebo and spironolactone groups. Each dot represents an individual patient.</p>
              </caption>
              <graphic xlink:href="jciinsight-8-154164-g195" position="float"/>
            </fig>
            <table-wrap position="float" id="T1">
              <label>Table 1</label>
              <caption>
                <title>Clinical and analytical data at the time of renal biopsy</title>
              </caption>
              <graphic xlink:href="jciinsight-8-154164-g196" position="float"/>
            </table-wrap>
            <table-wrap position="float" id="T2">
              <label>Table 2</label>
              <caption>
                <title>Clinical and analytical data at the time of urine sample</title>
              </caption>
              <graphic xlink:href="jciinsight-8-154164-g197" position="float"/>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
